

CUMULATIVE INDEX 1998

Volume 82

January	WOMEN'S HEALTH ISSUES, PART I, pages 1-188
March	WOMEN'S HEALTH ISSUES, PART II, pages 189-408
May	CURRENT CONCEPTS OF THROMBOSIS, pages 409-664
July	PREVENTION AND TREATMENT OF DIABETES AND ITS COMPLICATIONS, pages 665-979
September	OFFICE DERMATOLOGY, PART I, pages 981-1215
November	OFFICE DERMATOLOGY, PART II, pages 1217-1444

Note: Page numbers of article titles are in **boldface** type

- Abdominal surgery, thromboprophylaxis for, 486
- Abscesses, in HIV-infected patients, 1045-1046
- Acanthamebiasis, 1052
- Acantholysis, 1240
- Acanthosis nigricans, 1192-1193
benign versus malignant, 1364-1365
- Acarbose, for impaired glucose tolerance, 815-816
- ACE inhibitors, for diabetic nephropathy, beneficial effects of, 888-891
- Acetohexamide, for type 2 diabetes treatment, 766
- Acetretin, in psoriasis, 1410
- Acne, **1145-1154**
in children, 1392-1393
pathogenesis and etiology, 1145-1148
preconception recommendations in, 273
terminology, 1146
therapy, 1411
corticosteroids, 1151
isotretinoin, 1151-1152
oral, 1150-1151
topical, 1148-1150
- Acne rosacea, 1359-1360
- Acquired immunodeficiency syndrome, dermatologic manifestations of, 1402
- Acrochordons, 1302-1303
- Actinic dermatitis, chronic, in HIV-infected patients, 1062
- Acute cutaneous lupus erythematosus, 1360
- Acyclovir, 1405-1406
for herpes simplex infections, 1022, 1095-1096
resistance, 1406-1407
for varicella-zoster infections, 1023-1024, 1038
- Acyated plasminogen streptokinase activator complex, for central nervous system diseases, 551
- Adapalene, in acne, 1149
- Adolescents, diabetes in, **721-738**
- Adoption, in infertility, 290
- Adrenal hyperplasia, and infertility in women, 283-284
- Age of women, infertility and, 275-276
peptic ulcer disease and, 29
- AIDS, dermatologic manifestations of, 1402
- Albright's syndrome, 1189
- Albumin, abnormal secretion of, definitions of, 881
- Albuminuria, in type 1 diabetes, 666
- Alcohol, in women, abuse of, 378-381
colon carcinoma and, 326
infertility and, 278-279
liver disease and, 58-60
- Aldose reductase inhibitors, for diabetic neuropathy, 922
for diabetic retinopathy, 864-865
- Allergic contact dermatitis, 1117, 1120-1122
- Allergic dermatoses, **1105-1133**
bullous disease and autoimmune diseases, 1114-1115

- Allergic dermatoses (*Continued*)
 drug allergy, 1127-1130
 eczemas, 1115-1127
 Gell and Coombs classification of, 1106
 historical perspective and definitions, 1105-1106
 urticaria, 1106-1114
- Allokinesis, 1124
- Alopecia, 1155-1169
 in children, 1394
 evaluation, 994, 1156-1157
 with heparin treatment, 654
 in HIV-infected patients, 1066
 nonscarring, alopecia areata, 1161-1163
 androgenetic alopecia, 1158
 senescent alopecia, 1158-1159
 syphilitic alopecia, 1163-1164
 telogen effluvium, 1159-1161
 tinea capitis, 1166-1167
 traction alopecia, 1165-1166
 trichotillomania, 1164-1165
 scarring, 1167-1168
- Alpha-lipoic acid, for diabetic neuropathy, 922-923
- Alzheimer's disease, preventive hormone therapy for, 312-313
- Amitriptyline, as antihistamine, 1113
- Amyopathic dermatomyositis, 1227-1228, 1362
- Anaphylactoid reaction, 1110
- Anaphylaxis, 1110
- Anecd, in heparin-induced thrombocytopenia, 642
- Androgenetic alopecia, 1158
- Androgen(s), excess of, and infertility in women, 281-282
 in hormone replacement therapy, 304-305
 preconception recommendations in, 273
- Angioedema, 1112
- Angiofibromas, in tuberous sclerosis, 1204
- Angiomatosis, bacillary, in HIV-infected patients, 1047-1048
- Angiotensin-converting enzyme inhibitors, for diabetic nephropathy, beneficial effects of, 888-891
- Angular cheilitis, 1018, 1019
- Anorexia nervosa, complications, 146-148
 evaluation, 375
 multidimensional model, 148-152
 attitudes toward food, 150
 hunger and satiety, 149-150
 neurochemical abnormalities, 151
 role of serotonin, 151-152
 treatment, 152-156
 hospitalization, 153
 inpatient, 153-155
 outpatient, 152-153
 pharmacotherapy, 155
- Anterior chamber angle, neovascularization of, in diabetic retinopathy, 858-860
- Anthralin, in psoriasis, 1140
- Antibiotics, for acne, 1149-1151
 for *Staphylococcus* skin infection, 1002
- Anticardiolipin antibodies, detection of, in antiphospholipid syndromes, 440-442
- Anticardiolipin-thrombosis syndrome, 437
 clinical manifestations of, 434-436
- Anticoagulant complexes, 603
- Anticoagulants, antithrombin agents as, 569-586
 oral, monitoring tests for, 604
 for thromboprophylaxis, 484
 for venous thromboembolism, 502
 low-molecular-weight heparins, 504-505
 optimal duration of, 503-505
- Antidepressants, tricyclic, as antihistamines, 1113-1114
- Antiemetic exercises, for deep venous thrombosis, 631-632
- Antihistamines, in urticaria, 1113-1114
- Antihypertensive drug, ideal, characteristics of, 896
- Antileukotriene therapy, 1114
- Antimalarials, in cutaneous lupus erythematosus, 1224
- Antinuclear antibodies, in cutaneous lupus erythematosus, 1222-1223
- Antiphospholipid antibody syndrome, in women, 89-90
 during pregnancy, 260-261
- Antiphospholipid syndromes, laboratory diagnosis of, 439-442
 detection of anticardiolipin antibodies, 440-442
 detection of lupus anticoagulants, 439-440
 thrombocytopenia and, 439
- Antiphospholipid-thrombosis syndromes, 433-442
 antithrombotic regimens for, 438
 classification of, 436-442
 clinical manifestations of, 433-434
- Antiplatelet agents, in heparin-induced thrombocytopenia, 643, 645
- Antithrombin, 569-586. See also *Thrombin inhibitors*.
 activity, 414
 clinical application of, 574-578
 concentrates, for antithrombin deficiency, 418
 defects, pathologic decreases in, 414-418
 thrombosis and, 412-418
 deficiency, acquired, 417-418
 congenital, characteristics of, 416
 hereditary, 414-416

- mechanisms of, 415
- treatment of, 418
- development, 583
- structure, 571
- Antithrombin III, activity of, 413
- Antithrombotics, antithrombin agents as, 569-586
- Anxiety, in cancer patient, 330
 - in older women, 137
 - and somatization in women, 368-371
- Anxiety-depressive disorder, mixed, 360
- Aortic aneurysm, in women, 7
- Aortic disorders, congenital, in women, 6-7
- Aortic dissection, in women, 7-8
- Aphthosis, oral, 1410-1411
- Aphthous ulcers, in HIV in women, 343
- Aptamers, as thrombin inhibitors, 570, 574
- Argatroban, for heparin-induced thrombocytopenia, 576-577
 - as thrombin inhibitor, 572, 576
- Arginine peptides, as thrombin inhibitors, 572
- Arrhythmias, cardiac, during pregnancy, 251-252
- Arterial blood gas measurement, in pulmonary embolism diagnosis, 467-468
- Arteries, atherosclerotic occlusive disease of, in women, 12-13
 - recanalization of, with intra-arterial plasminogen activator, 554
- Arteritis, temporal, in women, 93-95
- Arthritis. See *Osteoarthritis; Rheumatoid arthritis*.
- Arthropod infections of skin, 1011-1015, 1049-1052, 1098-1100
 - in children, 1387-1388
- Asherman's syndrome, and infertility in women, 286-287
- Ash leaf macules, 1203-1204
- Aspergillus* infection, in HIV-infected patients, 1054
- Aspirin, for diabetic retinopathy, 866-867
- Asthma, in women, during pregnancy, 255-256
 - smoking and, 193
- Atherosclerosis, cerebral embolism and, 531
 - in women, 12-13
 - risk factors for, 2-3
- Athlete's foot, 1016
- Athletic activity, and infertility in women, 277-278
- Atopic dermatitis, 1123-1124
 - in children, 1389
 - diagnosis, 1124-1126
 - in HIV-infected patients, 1061
 - management, 1126-1127, 1409
- Atorvastatin, for dyslipidemia in diabetes, 943
- Atrophy, skin, 990
- Autoimmune connective tissue diseases, 1114-1115
- Autoimmune liver disease, in women, 57
- Autoimmune response, and type 1 diabetes, 739
- Autonomic neuropathy, diabetic, 912, 923
- Azelaic acid, in acne, 1149
- Azure lunula, 1182
- Bacillary angiomatosis, in HIV-infected patients, 1047-1048
- Bacterial infections of skin, 1001
 - cellulitis, 1007
 - in children, 1386-1387
 - ecthyma, 1005
 - erysipelas, 1006
 - folliculitis, 1003-1004
 - furuncles and carbuncles, 1004-1005
 - in HIV-infected patients, bacillary angiomatosis, 1047-1048
 - folliculitis, abscesses, furuncles, impetigo, and related infections, 1045-1046
 - mycobacterial infections, 1048
 - syphilis, 1049
 - impetigo, 1001-1003
 - Lyme disease, 1010-1011
 - necrotizing fasciitis, 1007
 - syphilis, 1007-1010
 - therapy, 1408
- Bacteriuria testing, in women, high-risk factors for, 234
- Balanitis, 1018, 1019
- Barrett's esophagus, in gastroesophageal reflux disease, 24
- Bartonella* infections, 1034-1035, 1047
- Basal cell carcinoma, 1310-1312
 - in HIV-infected patients, 1067, 1068
 - in nail bed, 1181
- Basal cell nevus syndrome, dermatologic manifestations of, 1401
- Basal (HOE-901) insulin, for type 1 diabetes, 698-699
- Basal metabolic rate, in eating disorders in women, 373
- Basement membrane hyperplasia, in diabetic neuropathy, 919
- Basophils, in urticaria, 1107-1111
- Becker's melanosis (nevus), 1193-1194
- Behavioral therapy, for obesity, 169-171
- Behçet's disease, genital ulcers in, differential diagnosis, 1083
- Benzathine penicillin G, in syphilis, 1088
- Benzoyl peroxide, for acne, 1149

- BESLE, 1264-1265
- Beta cell islets, destruction of, antigen-specific and nonspecific mechanisms of, 746-747
- immune response causing, role of T cells in, 744
- Bethesda system, for Pap test reporting, 235
- Biguanides, for impaired glucose tolerance, 815
- for type 2 diabetes treatment, 770-772
- Biliary cirrhosis, primary, in women, 55-56
- Binge/purge eating, evaluation of, 375
- Biopsy, in breast disease, techniques for, 209-211
- in melanoma, 1339, 1344-1345, 1349-1350
- shave, 999
- skin, 998-999
- in children, 1381-1382, 1384
- Bipolar disorder, preconception recommendations in, 273
- Blastomycosis, in HIV-infected patients, 1054
- Bleeding. *See Hemorrhage.*
- Bleomycin, hyperpigmentation from, 1196-1197
- Blistering diseases, **1239-1283**
- bullous eruption of systemic lupus erythematosus, 1264-1265
- bullous pemphigoid, 1252-1256
- chronic bullous dermatosis of childhood, 1258-1261
- cicatricial pemphigoid, 1256-1258
- dermatitis herpetiformis, 1265-1267
- epidermolysis bullosa acquisita, 1261-1264
- herpes gestationis, 1269-1271
- inherited epidermolysis bullosa, 1271-1281
- linear IgA dermatosis, 1267-1269
- pemphigus, 1240-1252
- Blood pressure, control of, in diabetic retinopathy, 861-862
- Blue nevus, 1330, 1332
- Body image, distorted, in eating disorders in women, 375
- Body mass index, calculation of, formula for, 162
- health risk and, 168
- relative risk of death and, 164
- Body shape, in obesity, 165-167
- Body weight, regulation of, 163
- Boils (furuncles), 1004-1005
- Bone deposition, inhibition of, heparin and, 648
- Bone resorption, heparin and, 647
- Boronic acid derivatives, as thrombin inhibitors, 573
- Botryomycosis, in HIV-infected patients, 1046
- Bowenoid papulosis, 1040, 1067, 1068
- Breast cancer, 212-219
- characteristics, 212
- epidemiology and risk factors, 212-213
- invasive carcinoma, 214-216
- relative risk of, benign breast disease and, 208
- noninvasive carcinoma, 213-214
- risk of, with estrogen-progestin hormone replacement therapy, 305-306
- smoking and, 190
- treatment, adjuvant systemic therapy, 217-219
- axillary dissection, 216-217
- breast reconstruction after mastectomy, 216-217
- Breast conservation therapy, for invasive carcinoma, in women, 214
- Breast disease in women, **203-222**
- abnormal mammogram and, 208-209
- benign, and relative risk of invasive breast cancer, 208
- biopsy techniques for, 209-211
- cancer. *See Breast cancer.*
- common disorders, 203-211
- masses, 205-208
- nipple discharge, 205
- pain, 203-205
- Bronze diabetes, 985
- Brunsting-Perry localized cicatricial pemphigoid, 1256-1257
- Budd-Chiari syndrome, with oral contraceptives, 62-63
- Bulimia nervosa, complications, 146-148
- evaluation, 375
- multidimensional model of, 148-152
- attitudes toward food, 150
- hunger and satiety, 149-150
- neurochemical abnormalities, 151
- role of serotonin, 151-152
- treatment, 152-156
- hospitalization, 153
- inpatient, 153-155
- outpatient, 152-153
- pharmacotherapy, 156
- Bullae, 987
- Bullous diabeticorum, 1371
- Bullous diseases, 1114-1115
- Bullous eruption of systemic lupus erythematosus, 1264-1265
- Bullous impetigo, 1002
- Bullous pemphigoid, 1252-1256
- Busulfan, hyperpigmentation from, 1197
- Butterfly rash, in systemic lupus erythematosus, 84
- Café au lait macules, 1188-1190

- Calcipotriene, in psoriasis, 1139, 1409
- Calf vein thrombosis, risk factors, 479
in surgical patients, risk categories of, 615
- Calorie-restricted diets, for obesity, 169
- Cancer. See also *Skin cancer*.
internal, cutaneous signs of, 1376-1377
myositis and, 1229
- Cancer in women, 321-333
breast cancer, 212-219
colon carcinoma, 325-328
lung carcinoma, 322-324
older women, 139-140
therapy, 328-331
alopecia, 329
psychological issues, 329-330
psychotherapy, 330-331
- Candida* onychomycosis, 1175
- Candidiasis, cutaneous, 1017-1019
in HIV infection, 1052-1053
vulvovaginal, in HIV infection, 341-342
- Captopril, effect on creatinine concentration, in diabetic nephropathy, 890-891
pemphigus from, 1244
- Carbohydrates, counting, in intensive treatment of type 1 diabetes, 710
metabolism, in older persons, 792-793
- Carbuncles, 1004-1005
- Cardiac arrhythmias, during pregnancy, 251-252
- Cardiac chambers, thrombosis originating in, 516-517
- Cardiopulmonary disease in pregnancy, 251-256
arrhythmias, 251-252
asthma, 255-256
ischemic heart disease, 252-253
pulmonary edema, 253-255
- Cardiovascular disease, in diabetes, epidemiology, 931-932
increased risk of, with
microalbuminuria, 892-893
risk factors for, 932-934
thrombosis and, 410, 511-522
in women, 1-19, 239
coronary artery disease, 1-5
older women, 131-132
vascular disease, 6-15
- Caregivers of older women, 129
- Carotid artery, stenosis, asymptomatic, in women, 9
and cerebral embolism, 534
thrombosis, and cerebral embolism, 533
- Carotid artery territory, ischemia of, 548-549
intra-arterial plasminogen activators for, 552-556
- Caterpillar bodies, 1063
- CBDC, 1258-1261
- Cellulitis, 1007
stasis dermatitis versus, 1364
Sweet's syndrome versus, 1362-1363
- Central centrifugal scarring alopecia, 1168
- Central nervous system diseases, neurologic status in, 547-549
plasminogen activators for, 545-568
- Cephalexin, for *Staphylococcus* skin infection, 1002
- Cerebellar hematoma, direct infusion
thrombolysis for, 560
- Cerebral embolism, large- and medium-size vessel thrombosis and, 530-535
pathophysiology, 528-530
small vessel thrombosis and, 535-538
- Cerebral infarction, evolution of, 525-528
ischemic penumbra in, 526-527
spreading depressions in, 527-528
- Cerebriform tongue, 1241
- Cerebrovascular disease, focal ischemia, 546-547
thrombosis and, 523-544
in women, 8-12
- Cervical ectopy, and HIV infection, 337
- Cervical neoplasia, in HIV infection, 339-341
- Chancroid, 1083, 1089-1091
- Charcot foot deformity, in diabetes, 966-969
reconstruction in, 968
ulceration with, 954
- Cheilitis, angular, 1018, 1019
- Cherry hemangiomas, 1298-1300
- Chest radiograph, in pulmonary embolism
diagnosis, 467
- Chest trauma, blunt, and acute coronary
thrombosis, 513-515
- Chickenpox, 1022, 1023
- Child abuse, cutaneous manifestations of, 1397
- Children. See also *Pediatric dermatology*.
diabetes in, 721-738
- Chloroquine, in cutaneous lupus
erythematosus, 1224
- Chlorpropamide, for type 2 diabetes
treatment, 766
- Cholestasis, intrahepatic, of pregnancy, 64-66
with oral contraceptives, 61
- Chronic actinic dermatitis, in HIV-infected
patients, 1062
- Chronic bullous dermatosis of childhood, 1258-1261
- Chronic obstructive pulmonary disease, smoking and, in women, 192-193
- Cicatricial pemphigoid, 1256-1258
- Cigarette smoking. See *Smoking*.
- Cimetidine, for warts, 1407
- Circle of Willis, atherosclerotic plaque in, and cerebral embolism, 534

- Clarke's (dysplastic) nevi, 1287-1288, 1326
- Claudication, intermittent, peripheral arterial occlusion and, 517
- Claw toes, in diabetic motor neuropathy, 951
- Clindamycin, in acne, 1149-1150
in *Staphylococcus* skin infection, 1002
- Coagulation abnormalities, in diabetes, 937-939
- Coccidioidomycosis, in HIV-infected patients, 1054
- Cognitive change, in behavioral therapy for obesity, 170
- Cold sores, 1021
- Collagen vascular diseases, **1217-1237**
dermatomyositis, 1224-1231
lupus erythematosus, 1217-1224
scleroderma, 1231-1236
- Colon carcinoma. See also *Colorectal cancer*.
in women, 325-328
- Colonoscopy, in women, high-risk factors for, 234
- Colorectal cancer. See also *Colon carcinoma*.
smoking and, in women, 190
- Colposcopy, indications, 236
- Compound nevi, 1286, 1330
- Compression stockings, graduated, for thrombophylaxis, 485
- Condoms, 1101-1102
- Condylomata acuminata, 1026, 1027, 1096-1098
in HIV-infected patients, 1040, 1041-1042, 1043, 1098
- Congenital malformations, in diabetes, 826-828
- Contact dermatitis, 1117
diagnosis, 1117, 1120-1122
irritant versus allergic, 1117, 1121
management, 1122
- Contraception, discontinuing, in infertility in women, 274
- Contraceptives, oral, activated protein C cofactor defect and, 425
antithrombin deficiency and, 417
estrogen-containing, thromboembolism prophylaxis with, 620
gastroesophageal reflux and, 27
liver effects of, 60-63
Budd-Chiari syndrome, 62-63
cholestasis, 61
hepatic tumors, 61-62
- Contrast venography, ascending, in pulmonary embolism diagnosis, 466
- Core-cutting needle biopsy, for breast disease in women, 210
- Coronary artery thrombosis, 511-512
- Coronary heart disease, preventive hormone therapy for, 310-312
risk factors for, 932
in diabetes with lipid abnormalities, 938
in type 1 diabetes, 671
in type 2 diabetes, hyperinsulinemia and, 681-682
mortality from, 679
in women, 1-5
acute myocardial infarction, 4-5
evaluation for ischemic heart disease, 3-4
older women, 131
revascularization, 5
risk factors for atherosclerosis, 2-3
- Coronary thrombosis, acute, with blunt chest trauma, 513-515
- Corticosteroids, in acne, 1151
in allergic contact dermatitis, 1122
in bullous pemphigoid, 1254-1255
in children, 1382
in cutaneous lupus erythematosus, 1224
in myositis, 1229-1230
in pemphigus, 1250
peptic ulcer disease and, in women, 31
in psoriasis, 1139, 1141
topical, potency ranking of, 1383
in urticaria, 1114
- Cotton-wool spots, in diabetic retinopathy, 849-851
- Cowden's disease, 1376, 1377
- Cowdry bodies, 1038
- Cradle cap, 1390
- CREST syndrome, 1235, 1364
- Crohn's disease, genital ulcers in, differential diagnosis, 1083
in women, 40-41
- Crotamiton 10%, 1100
- Cryotherapy, for genital warts, 1042, 1098
- Cryptococcosis, in HIV-infected patients, 1053
- Cutaneous lupus erythematosus. See *Lupus erythematosus, cutaneous*.
- Cutaneous manifestations of systemic diseases, **1359-1379**
- Cutaneous T cell lymphoma, in HIV-infected patients, 1069-1070
- Cyclosporin A, in urticaria, 1114
- Cyclosporine, in atopic dermatitis, 1409
- Cystic breast lesions, clinical management of, 207
- Cysts, digital mucous, 1172, 1183
skin, 1303-1305
- Cytokines, in HIV-related skin diseases, 1034
in immune response regulation, 741-743
pancreatic islet beta cell destruction and, in type 1 diabetes, 745
- Cytomegalovirus infection, in HIV-infected patients, cutaneous manifestations of, 1038-1039

- Dacarbazine, in melanoma, 1352-1353
- Darier's sign, 1399
- Death, relative risk of, body mass index and, 164
- Deep venous thrombosis. See also *Venous thromboembolism*.
 diagnosis, 459-576
 ascending contrast venography, 466
 Doppler ultrasound, 464
 evaluation for, 471
 history, 460-461
 iodone-125 fibrinogen uptake, 463-464
 laboratory evaluation for, 470-471
 magnetic resonance imaging, 466-467
 modalities, 462-470
 physical examination, 462
 plethysmography, 463
 real-time B-mode compression ultrasound for, 464-465
 real-time B-mode ultrasound with color Doppler, 465-466
 recommended strategies, 471-473
 heparin trials for, 592
 incidence, 409-410
 lower-extremity, suspected, alternative diagnoses in, 460
 prophylaxis, 477-493
 risk of, with estrogen-progestin hormone replacement therapy, 306
 treatment, 495-510
 aims of, 495-496
 future perspectives on, 505-507
 home, 506-507
 outpatient, antiembolic arm exercises, 632
 antiembolic leg exercises, 631-632
 guidelines, 630-632
 role of, 630
 strategies, 496-505
 initial phase, 496-502
 inferior vena cava filters, 497
 low-molecular-weight heparin, 498-501
 thrombectomy, 496-497
 thrombolytic therapy, 496
 unfractionated heparin, 497-498
 long-term, 502
 thrombin inhibitors, 505-506
 unfractionated heparin for, 492-498
 osteoporosis with, 651
- Dementia, in older women, 137
- Depression, in cancer patient, 330
 in women, 361-364
 menopause and, 362
 older women, 136
 risk of, 361
 self-in-relation theory, 364-368
 with smoking cessation, 194-195
 thyroid function, 362-363
- Dermatitis, 1117, 1120-1122
 atopic. See *Atopic dermatitis*.
 chronic, psoriasis versus, 1137
 contact. See *Contact dermatitis*.
 examination for, 992
 in HIV-infected patients, 1055, 1061, 1062
 seborrheic. See *Seborrheic dermatitis*.
 Dermatitis herpetiformis, 1265-1267
- Dermatofibroma/histiocytoma, 1296
- Dermatofibromas, 1295-1296
- Dermatofibrosarcoma protuberans, 1318-1320
- Dermatologic surgery, 1411-1412
- Dermatology, office, acne and rosacea, 1145-1154
 allergic dermatoses, 1105-1133
 benign neoplasms, 1285-1307
 blistering diseases, 1239-1283
 collagen vascular diseases, 1217-1237
 cutaneous manifestations of systemic diseases, 1359-1379
 hair diseases, 1155-1169
 HIV infection, 1033-1080
 infectious diseases, 1001-1031
 malignant melanoma, 1325-1358
 nail disorders, 1171-1183
 nonmelanoma skin cancer, 1309-1323
 pediatric, 1381-1403
 pigmentary diseases, 1185-1207
 psoriasis, 1135-1144
 sexually transmitted diseases, 1081-1104
 skin examination, 981-999
 therapy, 1405-1414
- Dermatomyositis, 1224-1225
 classification, 1225
 clinical manifestations, 1225-1228
 course and therapy, 1229-1231
 evaluation, 1229, 1230
 malignancy and, 1229
 seborrheic dermatitis versus, 1361-1362
- Dermatomyositis-siné-myositis, 1227-1228
- Dermatophytosis, 1015-1017, 1118
 in children, 1383, 1387
- Dermatoscope, 1337
- Dermatosis papulosa nigra, 1294
- Dexfenfluramine (Redux), for obesity
 treatment, 174-175
- Diabetes Control and Complications Trial, 665, 726-727
- Diabetes mellitus, cardiovascular disease
 in, 931-932. See also *Cardiovascular disease*.
 in children and adolescents, 721-738
 diabetic ketoacidosis treatment to reduce risk of fatal cerebral edema, 722-726
 role of intensive management and risk of hypoglycemia, 726-731

Diabetes mellitus (*Continued*)

- glycemic targets in, 728-729
- hypoglycemia prevention, 731
- hypoglycemia reduction, 730
- hypoglycemic seizures, 729-730
- neurocognitive outcome, 729
- type 1 versus type 2, differentiation of, 732-734
- coagulation abnormalities in, 937-939
- cutaneous manifestations of, 1370-1372
- dyslipidemia in, treatment of, 939-943
- endothelial cell function abnormalities in, 937-939
- foot problems in, **949-971**. See also *Foot problems*.
- glycemic control in, changes in serum lipids and lipoproteins, 940
- infertility in women and, 284
- lipid abnormalities in, 935-937
- nephropathy and hypertension in, **877-907**
- in older persons, **791-803**
 - carbohydrate metabolism, 792-793
 - chronic complications and glycemic control, 796-797
 - diagnosis, 794
 - disease presentation and manifestations, 793-794
 - hyperglycemic hyperosmolar nonketotic syndrome, 794-796
 - long-term management, 797-800
 - preconception recommendations in, 273
 - pregnancy and, 258-260. See also *Pregnancy, diabetes in*.
- in preteen children, intensive management in, pros and cons of, 727-728
- as risk factor, for atherosclerosis in women, 2
- type 1, average daily blood glucose levels in, 668
 - coronary heart disease risk in, 671
 - as disorder of immunoregulation, 740-741
 - dominance of Th1 over Th2 cells in, 743-746
 - economic cost of, 673
 - glycosylated hemoglobin levels in, 668
 - hypoglycemic reactions in, 673
 - intensive treatment of, **689-719**
 - definitions in, 690-692
 - diabetes team in, 692-693
 - elements of, 691
 - insulin pharmacology in, 693-699. See also *Insulin*.
 - risks of meticulous control, 710-712
 - hypoglycemia, 711-712
 - worsening of retinopathy, 710-711
 - strategies for, 699-710
 - algorithms, 708-709
 - carbohydrate counting, 710
 - flexible, 701-708
 - basal NPH or Lente, 702-703
 - basal Ultralente, 703-705
 - continuous subcutaneous infusion, 705-708
 - once- and twice-daily, 700-701
 - macrovascular complications in, 672
 - microvascular complications in, 666-671
 - pathogenesis of, current formulation of, 742
 - prevention of, **739-755**
 - future directions in, 750-751
 - intensive insulin therapy for, 749
 - possibility of, 748-750
 - retinopathy changes in, in primary versus secondary prevention, 669
 - retinopathy risk in, 672
 - severe hypoglycemia risk in, 673
 - studies of, baseline characteristics in, 667
 - as T cell-mediated autoimmune disease, 739-740
 - as Th1 cell/cytokine-mediated disorder, 747-748
 - urinary albumin secretion in, with intensive versus conventional treatment, 885
 - in primary versus secondary prevention, 670
- type 2, 674-684
 - cardiovascular mortality in, 681
 - in children and teens, 731-734
 - fasting blood glucose in, 676
 - glycosylated hemoglobin levels in, 676
 - hyperinsulinemia and coronary artery disease in, 681-682
 - hypoglycemia in, 684
 - length of survival with, 680
 - macrovascular complications in, 679-681
 - microvascular disease in, 674-679
 - myocardial infarction survival in, 683
 - natural history of, opportunity for prevention, 806-808
 - defective insulin secretion, 807-808
 - insulin resistance, 807
 - nephropathy changes in, primary vs secondary prevention, 678
 - pathogenesis of, 757-758
 - prevention of, **805-821**
 - approaches based on pathophysiology, 808
 - identification of subjects for, 808-810
 - points of intervention for, 809
 - program for, 816-817
 - strategies for, 811-814

- lifestyle modification, 811-813
 - combined diet and exercise, 812-813
 - dietary alteration, 811-812
 - increased physical activity, 812
- pharmacologic intervention, 813-816
 - acarbose, 815-816
 - biguanides, 815
 - sulfonylureas, 813-815
 - troglitazone, 816
- proteinuria in, effect of enalapril on, 889
- retinopathy changes in, 677
- risk factors for, 806
- studies of, baseline characteristics in, 675
- treatment of, 757-790
 - algorithm for, 784
 - biguanides, 770-772
 - adverse effects, 771-772
 - dosing, 772
 - efficacy, 771
 - mechanism of action, 770
 - combination therapy for, 781-782
 - including insulin, efficacy of, 774
 - diet, 758-762
 - adverse effects, 760
 - dosing, 760-762
 - efficacy, 758-760
 - mechanism of action, 758
 - drugs in development for, 782-785
 - agents reducing insulin resistance, 782-783
 - agents stimulating insulin secretion, 782
 - miscellaneous antidiabetic agents, 783-785
- exercise, 762-764
 - adverse effects, 763-764
 - dosing, 764
 - efficacy, 762-763
 - mechanism of action, 762
- α -glucosidase inhibitors, 772-776
 - dosing, 775
 - efficacy, 775
 - mechanism, 773-775
- insulin, adverse effects, 780-781
 - dosing, 781
 - efficacy, 780
 - mechanism of action, 780
- oral combination therapy for, efficacy of, 773
- recommendations for, 785
- sulfonylurea insulin secretagogues, 769-770
- sulfonylureas, 764-769
 - adverse effects, 767-768
 - dosing, 768-769
 - efficacy, 765-767
 - mechanism, 765
- thiazolidinediones, 777-779
 - adverse effects, 778-779
 - dosing, 779
 - efficacy, 777-778
 - mechanism, 777
 - weight gain in, 682-684
- vascular disease and lipids in, 931-948
- Diabetic ketoacidosis, cerebral edema risk in, 724-726
 - treatment protocols for, 723-724
 - treatment to reduce risk of fatal cerebral edema, in children and adolescents, 722-726
- Diabetic nephropathy, 877-907
 - burden of, 877-878
 - creatinine concentration in, effect of captopril on, 890-891
 - initiation and progression of, role of hyperglycemia in, 882-885
 - intervention studies, 883-885
 - mechanisms of damage, 882
 - observational studies, 882-883
 - role of hypertension in, angiotensin-converting enzyme inhibitors for, 888-891
 - antihypertensive drugs for, 887, 891-892
 - intervention studies, 888
 - mechanism of damage, 886
 - observation studies, 886
- maternal, progression in pregnancy, 825
- pathogenesis of, 879-882
 - ethnicity and genetic risk, 880
 - microalbuminuria, 881-882
 - natural history, 880-881
- prevention of, treatment for, 895-897
 - blood glucose control, 895
 - hypertension and microalbuminuria in, 895-896
 - protein intake, 896-897
- protein restriction effect on, 893-895
- screening for, 897
- treatment of, cost-effectiveness of, 897-898
- in type II diabetes, changes in, primary vs secondary prevention, 678
- Diabetic neuropathy, 909-929
 - definitions and classification, 910-914
 - autonomic, 912
 - distal sensory polyneuropathy, 913
 - erectile dysfunction, 912
 - mononeuropathies, 911
 - proximal motor (amyotrophy) neuropathy, 912
 - rapidly reversible hyperglycemic neuropathy, 911
 - sweating abnormalities, 913

Diabetic neuropathy (*Continued*)

- truncal polyneuropathy, 914
 - in diabetic foot problems, 951
 - epidemiology, 915-916
 - maternal, progression in pregnancy, 825
 - measures of, 914-915
 - natural history of, 916
 - pathogenesis, 920-921
 - pathology, 916-920
 - microangiopathy, 917-918
 - myelinated fibers, 916-917
 - painful neuropathy, 920
 - structure and function relationship, 919-920
 - symmetric sensory polyneuropathy, 920
 - unmyelinated fibers, 916
 - treatment, 921-924
 - current, 921-922
 - glycemic control, 921-922
 - symptomatic, 922
 - tricyclic drugs, 922
 - general aspects of, 923-924
 - potential, 922-923
 - aldose reductase inhibitors, 922
 - alpha-lipoic acid, 922-923
 - gamma-linolenic acid, 923
 - nerve growth factor, 923
- Diabetic retinopathy, 847-876
- changes in, in type 1 diabetes, primary versus secondary prevention, 669
 - classification of, 847
 - drug treatments, 864-868
 - aldose reductase inhibitors, 864-865
 - endothelial cell proliferation inhibitors, 867-868
 - histamine receptor antagonists, 867
 - pentoxifylline, 865-866
 - platelet inhibitors, 866-867
 - aspirin, 866
 - aspirin plus dipyridamole, 866-867
 - ticlopidine, 867
 - general medical treatments for, 860-864
 - blood lipid control, 863-864
 - blood pressure control, 861-862
 - fluid overload control, 862-863
 - glycemic control, 860-861
 - pregnancy, 864
 - renal function, 862
 - laser photocoagulation surgery for, focal, 868-870
 - macular edema, 868-870
 - panretinal, 870-871
 - proliferative retinopathy, 870
 - maternal, progression in pregnancy, 824-825
 - ophthalmoscopic and angiographic features of, 848-860
 - nonproliferative, 849-854

- cotton-wool spots, 849-851
 - fluorescein angiography of, 851
 - grading system for, 853-854
 - intraretinal hemorrhages, 850-851
 - lipid exudates, 850-851
 - macular edema, 852-853
 - microaneurysms, 849-851
 - venous beading, 850-852
 - proliferative, 854-860
 - iris neovascularization, 858-860
 - neovascularization, 854-856
 - preretinal (subhyaloid) hemorrhage, 856-857
 - traction retinal detachment, 857-858
 - vitreous hemorrhage, 857-858
 - pancreas transplantation and, 872
 - recommendations for, 872-874
 - risk of, in type 1 diabetes, 672
 - vitreotomy for, 870-871
 - worsening of, with meticulous control, 710-711
- Diaper dermatitis, 1390
- Dicloxacillin, for *Staphylococcus* skin infection, 1002
- Diethylpropion, for obesity treatment, 175
- Diet(s), colon carcinoma in women and, 325-326
 - for obesity treatment, calorie-restricted, 169
 - very-low-calorie, 172-173
- for older diabetic, in long-term management, 797
- in type 2 diabetes treatment, 758-762
 - adverse effects, 760
 - dosing, 760-762
 - efficacy, 758-760
 - mechanism of action, 758
- Dipyridamole, with aspirin, for diabetic retinopathy, 866-867
- Discoid lupus erythematosus, 1218-1219, 1360
- Dissecting cellulitis of scalp, 1168
- Distal subungual onychomycosis, 1173
- Domestic violence in women, 391-401
 - complexity of violent relationship, 392-393
 - definition of, 391-392
 - and health care system, 393-398. See also *Health care system*.
 - prevalence of, 392
 - screening protocol for, 394
- Donovanosis (granuloma inguinale), 1083, 1092-1094
- Doppler ultrasound, in deep venous thrombosis diagnosis, 464
- Dowling-Meara variant of epidermolysis bullosa, 1272
- Doxepin, as antihistamine, 1113-1114
- Doxycycline, in acne and rosacea, 1150-1151, 1153, 1411

- Drug allergy, 1127-1128
 characteristics, 1128
 diagnosis, 1128-1129
 immunologic mechanisms of, 1128
 treatment, 1129-1130
- Drug eruptions, cutaneous, eczematous, 1119
 in HIV-infected patients, 1064-1065
 hyperpigmentation, 1195-1197
- Drugs, illicit, and infertility in women, 278-279
- Dural sinus thrombosis, direct infusion
 thrombolysis for, 560
- Dysfibrinogenemia, congenital, and
 thrombosis, 432
- Dysfibrinolysis, and thrombosis, 429-430
- Dyslipidemia, in diabetes, treatment of,
 939-943
- Dysplastic (Clarke's) nevi, 1287-1288, 1326
- Eating disorders, 145-159
 classification of, 145-146
 multidimensional model of, 148-152
 attitudes toward food, 150
 hunger and satiety, 149-150
 neurochemical abnormalities, 151
 role of serotonin, 151-152
 treatment of, 152-156
 hospitalization, 153
 inpatient, 153-155
 outpatient, 152-153
 in women, 373-378
 evaluation of, 375-376
 factors in, 373-374
 medical risks of, 374
 pharmacotherapy for, 377-378
 treatment of, 376-377
- Ecarin clotting time, for antithrombin
 agent monitoring, 579
- Ecchymosis, 990
- Eclampsia, liver disease related to, 67-69
- Ecthyma, 1005
- Ectodermal dysplasia, dermatologic
 manifestations of, 1401
- Eczema, 1115-1116
 atopic dermatitis, 1122-1127
 contact dermatitis, 1117, 1120-1122
 differential diagnosis of, 1117, 1118-1119
- Eczematous and papulosquamous
 disorders, in children, 1389-1392
- Elderly. See also *Health of older women*.
 carbohydrate metabolism in, 792-793
 diabetes in, 791-803
- Electrocardiogram, for pulmonary
 embolism diagnosis, 467
- Electrocautery and desiccation, for genital
 warts, 1098
- Electrophysiology, in diabetic neuropathy
 measurement, 915
- Enalapril, effect on proteinuria, in type 2
 diabetes, 889
- Endocrine disorders, and infertility in
 women, 282-284
- Endometrial cancer, effect of smoking on,
 191
 risk of, with estrogen-progestin hormone
 replacement therapy, 306
- Endometriosis, 236-238
 effect of smoking on, 191
 infertility and, 285
- Endothelial cell, function of, abnormalities
 of, in diabetes, 937-939
 hypertrophy of, in diabetic neuropathy,
 919
 proliferation of, inhibitors of, for dia-
 betic retinopathy, 867-868
- Environmental concerns, in infertility in
 women, 274-275
- Eosinophilia, heparin and, 653
- Eosinophilia myalgia syndrome, 1236
- Eosinophilic fasciitis, 1235-1236
- Eosinophilic folliculitis, 1035
- Eosinophilic pustular folliculitis, in
 HIV-infected patients, 1059-1061
- Epidermodysplasia verruciformis, in
 HIV-infected patients, 1067, 1068
- Epidermoid cysts, 1303, 1304, 1305
- Epidermolysis bullosa, dermatologic
 manifestations of, 1401
 inherited, 1271
 classification, 1272-1273
 illustrations, 1274-1281
- Epidermolysis bullosa acquisita, 1261-1264
- Epiluminescence microscopy, 998, 1337
- Epithelium, oral, examination of, 993
- Epstein-Barr virus, in HIV-infected
 patients, cutaneous manifestations of,
 1039-1040
- Erectile dysfunction, with diabetic
 neuropathy, 912
- Erosions, 987
- Erysipelas, 1006
- Erythema, 991-992
 malar, 1222
 migratory necrolytic, 1377
- Erythema chronicum migrans, 1010
- Erythema gyratum repens, 1377
- Erythema infectiosum, 1028-1029
- Erythema multiforme, 1365-1366, 1410
- Erythema nodosum, 1366-1367, 1376
- Erythrasma, 998
- Erythromycin, in acne, 1149-1151
 in *Staphylococcus* skin infection, 1002
- Erythropoietic protoporphyria, 1375, 1401
- Esthiomene, 1091
- Estrogen, in hormone replacement therapy,
 301-302

- Estrogen (*Continued*)
 alternatives to, 308
 Estrogen therapy, gallstones and, 54
 Exanthems, in children, 1386
 Excisional biopsy, for breast disease, in women, 210-211
 Exercise, in obesity treatment, 171-172
 for older diabetic, in long-term management, 797-798
 for older women, 140
 in type 2 diabetes treatment, 762-764
 adverse effects, 763-764
 dosing, 764
 efficacy, 762-763
 mechanism of action, 762
 Eyelid, sebaceous carcinoma of, 1320
- Factor V Leiden, activated protein C resistance and, 426
 Factor Xa inhibitors, in heparin-induced thrombocytopenia, 645
 Famciclovir, 1406
 for herpes simplex infections, 1022, 1038
 Fasciitis, eosinophilic, 1235-1236
 Fast, modified, protein-sparing, for obesity treatment, 172-173
 Fasting glucose test, in women, high-risk factors for, 234
 Fat, regional distribution of, in obesity, 165-167
 Fatty liver, acute, of pregnancy, 66-67
 Fenfluramine (Pondimin), for obesity treatment, 174-175
 Fetal complications of smoking, 193
 Fetal thyroid, in thyroid disease in pregnancy, 115
 Fetal wastage, anticardiolipin-thrombosis syndrome and, 435-436
 syndrome of, incidence of, 410-411
 Fever blisters, 1021
 Fibrinolytic system defects, and thrombosis, 429-432
 Fibroadenomas, in women, 206
 Fibrocystic breast disease, 190, 207
 Fibromyalgia, in women, 90-91
 Fibrous plaques, in tuberous sclerosis, 1204
 Fifth disease, 1028-1029
 Fine-needle aspiration biopsy, for breast disease in women, 209-210
 Fingernail sign, 1186
 Fluconazole, in onychomycosis, 1176
 Fluid overload control, in diabetic retinopathy, 862-863
 Fluid resuscitation, for diabetic ketoacidosis, 723
 Fluoride supplement, in women, high-risk factors for, 234
 Flushing disorders, lupus erythematosus and, 1359-1360
 Focal nodular hyperplasia of liver, with oral contraceptives, 62
 Fogo selvagem, 1243
 Folic acid antagonists, preconception recommendations in, 273
 Follicular hyperkeratosis, in children, 1389
 Folliculitis, 1003-1004
 in children, 1387
 eosinophilic, 1035, 1059-1061
 in HIV-infected patients, 1045-1046, 1059-1061
 Food, attitudes toward, in eating disorders, 150
 Foot problems, diabetic, **949-971**
 demographics, 949-950
 depth and ischemic classification, 956
 infections, 954-958
 neuroarthropathy, 967-969
 osteomyelitis, 958
 outpatient management, 959-960
 pathophysiology, 951-952
 risk factors, 950
 skin and nail care, 960
 ulcers, 952-955
 amputations for, 966-967
 casting for, 963
 debridement of, 961
 elective surgery for, 965-966
 evaluation and treatment of, 960-969
 non-weight bearing for, 961
 shoes and insoles for, 964-965
 Fordyce's condition, 1320
 Fordyce spots, 993
 Fosarnet, ulcers from, in HIV-infected patients, 1065
 for varicella-zoster infections, 1038
 Fungal and yeast infections of skin, candidiasis, 1017-1019
 in children, 1387
 dermatophytes, 1015-1017
 in HIV-infected patients, 1052
 blastomycosis, 1054
 candidiasis, 1052-1053
 cryptococcosis, 1053
 histoplasmosis, 1053
 miscellaneous infections, 1054-1055
 sporotrichosis, 1053-1054
 microscopic examination for, 997
 onychomycosis, 1172-1176
 pityriasis (tinea) versicolor, 1019-1020
 therapy, 1407-1408
 Furuncles, 1004-1005
 in HIV-infected patients, 1045-1046
- Gallbladder disease, risk of, with estrogen-progestin hormone replacement therapy, 306

- Gallstones in women, 51-55
 clinical manifestations, 52
 diagnosis, 52-53
 estrogen therapy and, 54
 obesity and, 55
 pathophysiology, 51-52
 pregnancy and, 53-54
 treatment, 53
- Gamma-linolenic acid, for diabetic neuropathy, 923
- Gangrene, streptococcal, 1007
- Gastric bypass, for obesity treatment, 178
- Gastric outlet obstruction, in peptic ulcer disease in women, 32
- Gastric stapling, in obesity, 177-178
- Gastroesophageal reflux disease, medications in, 25
 therapy, 26
 in women, 21-26
 clinical course, 23
 clinical manifestations, 22
 complications, 23-24
 diagnostic tests, 22-23
 management, 24-26
 pathophysiology, 22
- Gastrointestinal diseases in women, 21-50
 gastroesophageal reflux disease, 21-28
 inflammatory bowel disease, 38-43
 irritable bowel syndrome, 35-38
 oral contraceptives and, 27
 peptic ulcer disease, 28-35
 pregnancy and, 26-27
 scleroderma, 28
- Gell and Coombs classification of allergic dermatoses, 1106
- Gemfibrozil, for dyslipidemia in diabetes, 943
- Genetic factors, peptic ulcer disease and, in women, 29
- Genetic screening, in women, 272
- Genetic testing/counseling, in women, high-risk factors for, 234
- Genital neoplasia, in HIV in women, 339-341
- Genital tract infections, in HIV in women, 341-342
- Genital ulcers, differential diagnosis of, 1083
 in HIV in women, 342-344
- Geriatric assessment, comprehensive, of women, 130-131
- Gingivostomatitis, 1021
 herpetic, in children, 1386
- Glimepiride, in type 2 diabetes treatment, 766
- Glipizide, in type 2 diabetes treatment, 766
- Glucose, blood, average daily levels of, in type 1 diabetes, 668
 control of, for diabetic nephropathy prevention, 895
 control, in diabetic neuropathy, 921-922
 in diabetic retinopathy, 860-861
 importance of, 665-687
 intolerance, progression to diabetes, rates of, 810
 risks of, 809
- Glucose test, fasting, in women, high-risk factors for, 234
- α -Glucosidase inhibitors, for older diabetic, in long-term management, 798
 for type 2 diabetes treatment, 772-776
 dosing, 775
 efficacy, 775
 mechanism, 773-775
- Glyburide, for type 2 diabetes treatment, 766
- Glycosylated hemoglobin levels, in type 1 diabetes, 668
 in type 2 diabetes, 676
- Gotttron's papules, in dermatomyositis, 1225-1226, 1362
- Granuloma annulare, in children, 1393-1394
- Granuloma inguinale, 1083, 1092-1094
- Graves' disease, cutaneous manifestations of, 1373
 in pregnancy, 117-118
- Griseofulvin, in tinea capitis, 1166-1167
- Groove sign, 1091
- Gummas, 1008, 1087
- Gynecologic health and disease, 223-247
 abnormal Pap smear management, 225, 234-236
 cardiovascular disease, 239
 endometriosis, 236-238
 high-risk factors in, 234
 HIV infection, 243-245
 hormone replacement therapy, 238-239
 osteoporosis prevention, 239-240
 ovarian cancer prevention and detection, 240-242
 preventive medicine, 223-225
 recommended diagnostic procedures and laboratory tests, 13-18 years, 226-227
 19-39 years, 228-229
 40-64 years, 230-231
 65 years and older, 232-233
 tamoxifen for breast cancer prophylaxis, 242-243
- Gynecologic surgery, thromboembolism prophylaxis for, 619-621
 thromboprophylaxis for, 486
- Habit tic disorder, 1172, 1181, 1183
- Hair(s), classification and life cycle of, 1155

Hair(s) (*Continued*)

- disorders. See also *Alopecia*.
 - in children, 1394
 - in HIV-infected patients, 1065-1066
 - examination, 993-995
- Hair pull and hair pluck tests, 1157
- Hairy leukoplakia, oral, in HIV-infected patients, 1039-1040
- Half-and-half nails, 995
- Hallopeau type of pemphigus vegetans, 1241, 1243
- Halo nevi, 1292-1293
- Hand-foot-and-mouth disease, 1024-1025
- Health care of older women, financing of, 129-130
- Health care system, domestic violence and, 393-398
 - emergency department, 393-395
 - detection, 393-394
 - intervention, 394-395
 - primary care setting, 395-398
 - barriers to screening, 398
 - documentation, 398
 - education, 396
 - health problems, 396-397
 - intervention, 396
 - potential impact on children, 397-398
 - pregnancy, 397
 - reporting, 398
 - screening, 396
- Health of older women, 127-144
 - cancer, 139-140
 - cardiovascular disease, 131-132
 - comprehensive geriatric assessment, 130-131
 - demographics, 127-130
 - caregivers, 129
 - financing health care, 129-130
 - health status, 128
 - living circumstances, 128-129
 - oldest-old, 128
 - use of health services, 130
 - exercise, 140
 - mental health, 136
 - osteoporosis, 132-133
 - postmenopausal, hormonal treatment in, 134
 - sexuality, 137-138
 - substance abuse, 138-139
 - urinary incontinence, 134-135
- Health services, use by older women, 130
- Heart disease. See also *Cardiovascular disease*.
 - ischemic, evaluation of women for, 3-4
 - during pregnancy, 252-253
- Heart failure, in older women, 132
- Heart valves, prosthetic, and thrombosis, 515-516
- Helicobacter pylori*, peptic ulcer disease and, in women, 29-30
 - treatment regimens for, 34
- Heliotrope rash, in dermatomyositis, 1225
- HELLP syndrome, in pregnancy, 68-69
- Hemangiomas, cherry (adult acquired), 1298-1300
 - childhood, 1300-1302, 1398-1399
 - sclerosing, 1296
- Hemoglobin, measurement in women, high-risk factors for, 234
- Hemorrhage, in gastroesophageal reflux disease, 24
 - intraretinal, in diabetic retinopathy, 850-851
 - in peptic ulcer disease in women, 31-32
- Hemorrhagic infarction, with intra-arterial plasminogen activator, 555
- Henderson-Patterson bodies, 1044
- Heparin, for antithrombin deficiency, 418
 - cost considerations, 580
 - eosinophilia and, 653
 - low-molecular-weight, 590-591
 - for anticoagulation, in heparin-induced thrombocytopenia, 643-644
 - clinical acceptance and consensus statements, 627-632
 - cost-effectiveness of, 593
 - for deep venous thrombosis, 498-501
 - properties of, 590
 - for pulmonary embolism, 501-502
 - trials of, 592
 - unfractionated versus, 591
 - for venous thromboembolism, 504-505
- skin reactions to, 653-654
- as thrombin inhibitor, 575
- for thromboprophylaxis, 481
- unfractionated, 587-589
 - anticoagulant activity of, 587-588
 - complications of, 589
 - consensus statement on, 629
 - for deep venous thrombosis, 497-498
 - trials of, 592
- Heparin cofactor II, defects of, and thrombosis, 418-420
 - deficiency of, acquired, 420
 - congenital, 419
- Hepatic disease, cutaneous manifestations of, 1374
- Hepatic hemorrhage/rupture, in pregnancy, 69
- Hepatic tumors, with oral contraceptives, 61-62
- Hepatitis, acute, and antithrombin deficiency, 417
- Hepatitis B vaccine, in women, high-risk factors for, 234
- Hepatobiliary diseases in women, 51-75
 - alcohol and liver disease, 57-60
 - autoimmune liver disease, 57
 - chronic liver disease and infertility, 60

- gallstones, 51-55
- oral contraceptive effects on liver, 60-63
- pregnancy and liver disease, 63-69
- primary biliary cirrhosis, 55-56
- Herlitz type of epidermolysis bullosa, 1272
- Herpes gestationis, 1269-1271
- Herpes simplex infections, 1020-1022
 - in children, 1385-1386
 - examination of, 982
 - genital, 1083, 1094-1096
- Herpes simplex virus 2, in HIV infection
 - in women, 343-344
- Herpesvirus infections, in HIV-infected patients, cutaneous manifestations of, 1036-1038, 1096
 - therapy, 1405-1407
- Herpes zoster, 991, 1022-1024
 - in HIV-infected patients, 1036-1037
- Hip fracture, thromboprophylaxis for, 487
- Hip replacement, thromboprophylaxis for, 487, 617-618
- Hirsutism, 994
- Hirudin, as thrombin inhibitor, 570-571
 - cost considerations, 580
 - for heparin-induced thrombocytopenia, 576
 - trials of, 575
- Hirulog, as thrombin inhibitor, 570-571
 - trials of, 575-576
- Histamine, 1107
- Histamine antagonists, in urticaria, 1113-1114
- Histamine receptor antagonists, for diabetic retinopathy, 867
- Histiocytosis, dermatologic manifestations of, 1402
- Histochemical stains, in nonmelanoma skin cancer, 1312
- Histoplasmosis, in HIV-infected patients, 1053
- Hives. See *Urticaria*.
- HIV infection. See *Human immunodeficiency virus infection*.
- Hodgkin's disease, cutaneous, in HIV-infected patients, 1069
- Hormone replacement therapy, 134, 238-239, 301-316
 - decision for, approach to, 313-316
 - collaborative, 315
 - concerns and risks in, 315
 - goals in, 313
 - potential adverse effects, 313-315
 - selection of regimen, 316
- estrogen-progestin, risks of, 305-307
 - breast cancer, 305-306
 - deep vein thrombosis/pulmonary embolus, 306
 - endometrial cancer, 306
 - gallbladder disease, 306
 - systemic lupus erythematosus, 306-307
- menopause and, 297-320
- preventive, 309-313
 - for Alzheimer's disease, 312-313
 - for coronary heart disease, 310-312
 - for osteoporosis, 309-310
- regimens, 301-305
 - androgens, 304-305
 - estrogen, 301-302
 - options for, 302
 - progestin, 302-304
- symptomatic, 307-309
 - mood symptoms, 308
 - vaginal atrophy, 308-309
 - vasomotor symptoms, 307-308
- thromboembolism prophylaxis with, 620
- HPV infection. See *Human papillomavirus infection*.
- Human immunodeficiency syndrome, antidiolipin-thrombosis syndrome and, 436
- Human immunodeficiency virus infection, cutaneous manifestations of, 1033-1080
 - bacterial infections, 1045-1049
 - neoplastic disorders, 1067-1073
 - noninfectious skin disorders, 1055-1067
 - parasitic infections and ectoparasitic infestations, 1049-1052
 - pathogenesis of HIV-related skin diseases, 1034-1036
 - systemic fungal infections, 1052-1055
 - viral infections, 1036-1045
- maternal-child transmission of, smoking and, 193
- in women, 243-245, 335-357
 - effect on pregnancy, 345-346
 - epidemiology of, 335-336
 - gender differences in, 339
 - gender-specific complications of, 339-348
 - genital neoplasia, 339-341
 - genital tract infections, 341-342
 - genital ulcer disease, 342-344
 - pregnancy and, 261-263, 344-346
 - effect on HIV progression, 344-345
 - routine evaluation in, 348-352
 - complete physical examination, 349-350
 - laboratory evaluation, 350-351
 - thorough and complete medical history, 349
 - testing for, high-risk factors for, 234
 - transmission of, 336-337
 - cervical ectopy, 337
 - prevention of, 337-339
 - sexual, 336

- Human immunodeficiency virus infection
(*Continued*)
sexually transmitted diseases, 337
vertical, 346-348
- Human papillomavirus infection, in
children, 1384
in HIV-infected patients, cutaneous man-
ifestations of, 1040-1043
warts from, 1025-1026, 1096-1098
- Hunger/satiety, in eating disorders,
149-150
- Hutchinson's sign, 1179
- Hydroquinone, in melasma, 1190, 1191
- Hydroxychloroquine, in cutaneous lupus
erythematosus, 1224
in myositis, 1230-1231
- Hypercoagulability, with liver disease, 417
syndromes of, 409-458
- Hypercortisolism, and infertility in
women, 283
- Hyperemesis gravidarum, in pregnancy, 64
- Hyperglycemia, in elderly, nondietary
factors contributing to, 793
in initiation and progression of diabetic
nephropathy, 882-885
neonatal, with gestational diabetes, 832
- Hyperglycemic hyperosmolar nonketotic
syndrome, in older diabetic, 794-796
- Hyperglycemic neuropathy, rapidly
reversible, 911
- Hyper-IgE syndrome, 1119
- Hyperinsulinemia, accelerated
atherosclerosis with, 934
coronary artery disease and, in type 2 di-
abetes, 681-682
insulin resistance and, 934-935
- Hyperlipidemia, as risk factor for
atherosclerosis in women, 2-3
- Hyperpigmentation, 1185-1200
- Hyperprolactinemia, causes of, 281
infertility in women and, 280-281
- Hypertension, in diabetes, 877-907
nephropathy initiation and
progression, 885-892
nephropathy prevention, 895-896
pathogenesis of, 878-879
in older women, 132
preconception recommendations in, 273
pregnancy-related, effect of smoking on,
191
as risk factor for atherosclerosis in
women, 2
- Hyperthyroidism, cutaneous
manifestations of, 1372-1373
in women, 106-109
causes of, 107
human chorionic gonadotropin-in-
duced, in pregnancy, 118-119
infertility and, 283
maternal, in pregnancy, 116-117
thyroid function tests in, 107
treatment of, 108
- Hypertrichosis, 994
- Hypertrichosis lanuginosa, 1377
- Hypertrophic lupus erythematosus, 1219
- Hyperventilation, during pregnancy, 250
- Hypoglycemia, maternal unawareness of,
in pregnancy, 826
in type 1 diabetes, 673, 711-712
in type 2 diabetes, 684
- Hypopigmentation, 1200-1204
- Hypotension, orthostatic, in older women,
132
- Hypothyroidism, cutaneous manifestations
of, 1372-1373
in women, 104-106
causes of, 105
infertility and, 282-283
in pregnancy, 115-116
- Ichthyosis, 1377, 1401
- Id reaction, 1118
- Imaging, in melanoma, 1352-1353
in pulmonary embolism diagnosis, 462-
470
- Immune response, pancreatic islet beta cell
destruction and, antigen-specific,
746-747
role of T cells in, 744
regulation of, T-cell subsets and cytokine
products in, 741-743
- Immune system cells, and pancreatic islet
beta cell destruction, in type 1
diabetes, 745
- Immunization, for gynecologic health, 225
- Immunofluorescence testing, in cutaneous
lupus erythematosus, 1223
- Immunopathy, in diabetic foot problems,
952
- Immunoregulation, disorder of, type 1
diabetes as, 740-741
- Immunosuppressive agents, in bullous
pemphigoid, 1254-1255
in pemphigus, 1250
in recent-onset type 1 diabetes, 740
- Impetigo, 1001-1003
in children, 1386-1387
in HIV-infected patients, 1045-1046
- Incisional biopsy, for breast disease in
women, 211
- Incontinence, urinary, in older women,
134-135
- Incontinentia pigmenti, dermatologic
manifestations of, 1401
- Infectious diseases, in infertility in women,
274

- of skin, **1001-1031**
 - bacterial infections, 1001-1011
 - in children, 1384-1388
 - in diabetes mellitus, 1372
 - fungal and yeast infections, 1015-1020
 - in HIV-infected patients, **1033-1080**
 - infestations, 1011-1015
 - nail disorders, 1172-1177
 - sexually transmitted diseases, **1081-1104**
 - therapy, 1405-1408
 - viral infections, 1020-1030
- Inferior vena cava filters, for deep venous thrombosis, 497
- Infertility, male factor, 284
 - in women, **271-295**
 - adoption for, 290
 - advanced assisted reproductive technologies for, 290
 - causes of, 275-286
 - age, 275-276
 - alcohol and illicit drugs, 278-279
 - athletic activity and weight loss, 277-278
 - cigarette smoking, 277
 - ovulatory dysfunction, 279-280
 - pelvic inflammatory disease, 276-277
 - cervical factors, 287-288
 - chronic liver disease and, 60
 - chronic medical problems affecting pregnancy, 273
 - definitions, 271
 - discontinuing contraception, 274
 - evaluation and referral for, 289
 - infectious diseases, 274
 - nutritional assessment, 275
 - preconceptional counseling, 272-275
 - social and environmental concerns, 274-275
 - tubal and peritoneal factors, 285-286
 - unexplained, 288-290
 - uterine factors, 286-287
 - anomalies, 286
 - fibroids (leiomyomas), 287
 - synechiae, 286-287
- Infestations, in HIV-infected patients, 1049-1052
 - pediculosis, 1012-1015
 - scabies, 1011-1012, 1049-1051
- Inflammation, pigmentary changes following, 1197-1200
- Inflammatory bowel disease in women, 38-43
 - Crohn's disease, 40-41
 - genetic factors, 39
 - management of, 41-42
 - pregnancy and, 42-43
 - ulcerative colitis, 39-41
- Inflammatory skin conditions, in children, 1392-1397
 - therapy, 1408-1411
- Influenza vaccine, in women, high-risk factors for, 234
- Inherited epidermolysis bullosa, 1271
 - classification, 1272-1273
 - illustrations, 1274-1281
- Insulin, defective secretion of, in type 2 diabetes, 807-808
 - for older diabetic, in long-term management, 799-800
- pharmacology, in intensive treatment of type 1 diabetes, 693-699
- self-administered, 696
- subcutaneously injected, basal (HOE-901), 698-699
 - bioavailability and absorption rate of, 694
 - intermediate-acting (NPH and Lente), 698, 702, 704
 - long-acting (Ultralente), 698-699, 706
 - pharmacokinetic parameters of, 694
 - rapid-acting (insulin lispro), 697-698, 705
 - region of administration of, 695
 - short-acting (regular), 696-697, 702, 704, 706
 - timing of, 695
- in type 2 diabetes treatment, 779-781
 - adverse effects, 780-781
 - dosing, 781
 - efficacy, 780
 - mechanism of action, 780
- Insulin resistance, accelerated atherosclerosis with, 934
 - hyperinsulinemia and, 934-935
 - in type 2 diabetes, 807
- Interferon, in condylomata acuminata, 1043, 1098
 - in melanoma, 1352
- Intermittent claudication, peripheral arterial occlusion and, 517
- International Normalized Ratio, calculation of, 605
 - lupus anticoagulant effect on, 608
- Intertrigo, candidal, 1017, 1018
- Intradermal nevi, 1286, 1330
- Intraretinal hemorrhages, in diabetic retinopathy, 850-851
- In vitro fertilization, smoking and, 190
- Iodine, radioactive, for hyperthyroidism, 108
- Iodine-125 fibrinogen uptake, in deep venous thrombosis diagnosis, 463-464
- Iris neovascularization, in diabetic retinopathy, 858-860

- Irritable bowel syndrome in women, 35-38
 associated factors, 36-37
 clinical manifestations, 36
 diagnosis, 37
 management, 38
 pathophysiology, 35-36
- Irritant contact dermatitis, 1117, 1120-1122
- Ischemic attacks, transient, in women, 9-10
- Ischemic heart disease, evaluation of
 women for, 3-4
 during pregnancy, 252-253
- Isotretinoin, in acne and rosacea,
 1151-1152, 1153, 1411
- Itchy red bump disease, 1059
- Itraconazole, in onychomycosis, 1176,
 1407-1408
- Ivermectin, 1012, 1408
- Jarisch-Herxheimer reaction, 1010
- Jewel cluster sign, 1259-1260
- Junctional nevi, 1230
- Kaposi's sarcoma, in HIV-infected
 patients, 1070-1073
- Keloids, 1297-1298
 in children, 1399-1400
- Keratoacanthoma, 1313-1315
- Keratosis pilaris, in children, 1389
- Knee, osteoarthritis of, management
 guidelines for, 94
- Knee replacement, thromboprophylaxis
 for, 487, 618
- Koebner phenomenon, 991, 1200
- Koebner variant of epidermolysis bullosa,
 1272
- Koenen tumors, 1204
- KOH examination, 997, 1383
- Koilonychia, 1182
- Koplik spots, 1029
- Lacunar infarcts, small vessel thrombosis
 and, 535
- Laser photocoagulation surgery, for
 diabetic retinopathy, 868-871
- Lead, preconception recommendations, 273
- Leg compression, intermittent, for
 thromboprophylaxis, 484-485
- Legs, ulcerations of, 1368-1370
- Leiomyomas, effect of smoking on, 191
 infertility in women and, 287
- Lentigo maligna, seborrheic keratoses
 versus, 1294
 surgical management of, 1346
- Lentigo simplex, 1330
- Leriche's syndrome, and peripheral
 arterial occlusion, 517
- Leser-Trélat, sign of, 1294, 1377
- Leukoplakia, oral hairy, in HIV-infected
 patients, 1039-1040
- Lice, 1012-1015
 in children, 1388
 pubic, 1100-1101
- Lichen planopilaris, 1168
- Lichen planus, 1172, 1178-1179
- Lichen striatus, in children, 1391-1392
- Lifestyle management, in gastroesophageal
 reflux disease, 25
 for gynecologic health, 223
 in peptic ulcer disease in women, 32
- Lindane cream or lotion, 1012, 1051,
 1099-1100
- Linear IgA dermatosis, 1267-1269
- Lipid exudates, in diabetic retinopathy,
 850-851
- Lipid profile, in women, high-risk factors
 for, 234
- Lipids, blood, control of, in diabetic
 retinopathy, 863-864
 in diabetes, 931-948
 abnormalities of, 935-937
- Lipohyalinosis, and lacunar infarct,
 536-537
- Livedo reticularis, 1222
- Liver, hemorrhage/rupture of, in
 pregnancy, 69
 oral contraceptive effects on, 60-63
- Liver cell adenomas, with oral
 contraceptives, 61
- Liver disease, chronic, and antithrombin
 deficiency, 417
 cutaneous manifestations of, 1374
 in women, alcohol and, 57-60
 autoimmune, 57
 chronic, and infertility, 60
 pregnancy and, 63-69. See also *Preg-*
nancy.
- Liver spots, 1332
- Livido reticularis, in anticardiolipin-
 thrombosis syndrome, 435
- Localized scleroderma, 1232
- Löfgren's syndrome, 1376
- Lovibond's angle, 995
- Lower extremity, ulcerations of, 1368-1370
- Lumbar spine, bone density of, with
 heparin treatment, 650
- Lung carcinoma, in women, 192, 322-324
- Lupus anticoagulants, detection of, in
 antiphospholipid syndromes, 439-440
- Lupus anticoagulant-thrombosis
 syndrome, clinical manifestations of,
 437-439
- Lupus erythematosus, cutaneous,
 1217-1218, 1360

- classification, 1218-1222
- evaluation, 1223
- laboratory abnormalities in, 1222-1223
- psoriasis versus, 1137
- therapy, 1223-1224
- discoid, 1360
- systemic, anticardiolipin-thrombosis syndrome in, 435
- bullous eruption of, 1264-1265
- rosacea/flushing versus, 1359-1360
- in women, 83-87
 - clinical features of, 83
 - diagnosis of, 85-86
 - drug-induced, 88-89
 - hormonal factors and, 88
 - laboratory features of, 86
 - major organ involvement in, 84
 - neuropsychiatric, 84-85
 - pregnancy and, 87-88, 260-261
 - renal disease in, 84
 - risks of, with estrogen-progestin hormone replacement therapy, 306-307
 - treatment of, 86-87
- Lupus pernio, 1376
- Lupus profundus, 1360
- Luteal phase defect, and infertility in women, 280
- Lyme disease, 1010-1011
- Lymphangioleiomyomatosis, in women, 199
- Lymph nodes, in melanoma, 1349-1350
- Lymphogranuloma venereum, 1083, 1091-1092
- Lymphoreticular malignancies, in HIV-infected patients, 1069-1070
- Macular edema, in diabetic retinopathy, 852-853
 - focal laser photocoagulation surgery for, 868-870
- Macules, 985
 - ash leaf, 1203-1204
- Magnetic resonance imaging, in deep venous thrombosis diagnosis, 466-467
- Malformations, congenital, in diabetes, 826-828
- Malignant melanoma, **1325-1358**
 - epidemiology, 1325-1330
 - examination and diagnosis, 1330
 - biopsy techniques, 1339, 1344-1345
 - clinical and laboratory evaluation, 1345
 - common benign pigmented lesions, 1330-1334
 - with dermatoscope (epiluminescence microscope), 1337
 - with photographs, 1339
 - skin examination, 1335-1336
 - with Wood's light, 1336-1337
 - in HIV-infected patients, 1067-1068
 - management, adjuvant therapy, 1352-1353
 - follow-up, 1353-1354
 - lymph node, 1349-1350
 - surgical, 1346-1349
 - moles and, 1288-1290
 - of nails, 1172, 1179-1180
 - pregnancy and, 1351-1352
 - prognostic variables, 1350-1351
- Mammography, high-risk factors for, 234
- Mast cells, in urticaria, 1107-1111
- Mastocytomas, in children, 1399
- Measles, 1029-1030
- Measles-mumps-rubella vaccine, in women, high-risk factors for, 234
- Mees' lines, 1182
- Melanin and melanocytes, 1185-1186
- Melanoacanthoma, 1294
- Melanocytic nevi. *See Nevi, melanocytic.*
- Melanoma. *See also Malignant melanoma.*
 - dermatologic manifestations of, 1402
- Melasma, 1190-1191
- Menopause, depression and, 362
 - diagnosis, 299
 - experience of, 298-301
 - epidemiology, 298-299
 - hormone changes, 299
 - hormone replacement therapy and, **297-320**
 - preventive hormone therapy for, 309-313
 - symptoms, 300-301
 - transition to, 299-300
- Mental health of women, **359-389**
 - anxiety and somatization, 368-371
 - depression, 361-364
 - self-in-relation theory of, 364-368
 - eating disorders, 373-378
 - factors that modify stress responses, 371-373
 - older women, 136
 - anxiety, 137
 - dementia, 137
 - depression, 136
 - substance abuse, 378-381
- Mercury, organic, preconception recommendations in, 273
- Merkel cell carcinoma, 1317-1318
- Metatarsal head, ulceration of, in diabetes, 953
- Metformin, in diabetes management, 798-799
- Methotrexate, in psoriasis, 1141, 1410
- Metronidazole, in rosacea, 1153
- Microalbuminuria, in diabetes, 666
 - increased cardiovascular disease risk with, 892-893

- Microalbuminuria (*Continued*)
 nephropathy prevention and, 895-896
 Microaneurysms, in diabetic retinopathy, 849-851
 Microangiopathy, in diabetic neuropathy, 917-918
 Microatheroma, and lacunar infarct, 537
 Migratory necrolytic erythema, 1377
 Milia, 1305
 Minocycline, for acne, 1150-1151, 1411
 hyperpigmentation from, 1195
 Mohs micrographic surgery, 1346-1349
 Moles. See also *Nevi, melanocytic*.
 melanoma and, 1326
 changing mole, 1289-1290, 1294
 checkup for, 1288-1289
 Molluscum contagiosum, 1027-1028
 in children, 1385
 in HIV-infected patients, 1043-1045
 Mononeuropathies, diabetic, 911
 Mood symptoms, in menopause, hormone replacement therapy for, 308
 Morphea, 1232
 scleroderma versus, 1363-1364
 Mucous cyst, digital, 1172, 1183
 Mucous membranes, examination of, 992-993
 Muehrcke's lines, 995, 1182
 Muir-Torre syndrome, 1376, 1377
 Mupirocin, 1408
 Mycobacterial infections, in HIV-infected patients, 1048
 Myocardial infarction, acute, 512-513
 incidence of, 410
 thromboembolism prophylaxis in, 622
 treatment of, 514
 in women, 4-5
 during pregnancy, 252
 survival in, in type 2 diabetes, 683
 Myositis. See *Dermatomyositis; Polymyositis*.
- Nail disorders, **1171-1183**
 dermatologic diseases affecting nails, 1177-1179
 differential diagnosis of, 1172
 digital mucous cyst, 1183
 habit tic disorder, 1181, 1183
 in HIV-infected patients, 1066-1067
 infectious, 1172-1177
 neoplastic, 1179-1181
 in systemic disease, 1182, 1183
 Nails, anatomy and terminology, 1171
 examination of, 995-996
 growth and kinetics, 1171
 Nausea, pregnancy-related, effect of smoking on, 191
 Necrobiosis lipoidica, 1411
 Necrobiosis lipoidica diabetorum, 1371
 Necrotizing fasciitis, 1007
 Needle localization biopsy, for breast disease, in women, 211
 Neoplasms, cutaneous. See *Skin, neoplasms*.
 Neovascularization, in diabetic retinopathy, 854-856
 Nephropathy, diabetic. See *Diabetic nephropathy*.
 Nerve growth factor, for diabetic neuropathy, 923
 Neumann type of pemphigus vegetans, 1241
 Neuralgia, postherpetic, 1023
 Neurochemical abnormalities, in eating disorders, 151
 Neurofibromatosis, dermatologic manifestations of, 1401
 Neurofibromatosis-1, 1188-1189
 Neurofibromatosis-2, 1189
 Neurologic disorders, in anticardiolipin-thrombosis syndrome, 435
 Neuropathy, diabetic. See *Diabetic neuropathy*.
 Neurosurgery, thromboprophylaxis for, 487, 617
 Nevi, Becker's nevus, 1193-1194
 blue, 1330, 1332
 compound, 1286, 1330
 congenital, 1291-1292, 1327-1330, 1398
 halo, 1292-1293
 intradermal, 1286, 1330
 junctional, 1230
 melanocytic, 1285
 atypical, 1287-1288
 in children, 1397-1398
 clinical encounters with, 1288-1290
 clinical features of, 1286-1287
 treatment, 1291-1293
 Nevus flammeus, 1301-1302
 Nickel dermatitis, 1391
 Nicotine replacement, with smoking cessation, in women, 196-197
 Nipple discharge, in women, 205
 Nodules, 986-987
 Nonsteroidal anti-inflammatory drugs, peptic ulcer disease and, in women, 30
 side effects of, 93
 Nummular eczema, 129
 Nutrition. See also *Diet*.
 assessment, in infertility in women, 275
- Obesity in women, **161-181**
 causes of, 162
 definition of, 162
 gallstones and, 55

- genetics of, 161
- health implications of, 164-165
- regional distribution of fat in, 165-167
- treatment of, 167-178
 - behavioral therapy, 169-171
 - calorie-restricted diets, 169
 - exercise, 171-172
 - goals of, 168-169
 - patient selection for, 167-168
 - pharmacologic, 173-177
 - commonly used drugs, 175
 - dexfenfluramine (Redux), 174-175
 - diethylpropion, 175
 - fenfluramine (Pondimin), 174-175
 - orlistat (Xenical), 175
 - phentermine, 175
 - sibutramine (Meridia), 175-176
 - studies of, 173-174
 - protein-sparing modified fast, 172-173
 - surgical procedures, 177-178
 - very-low-calorie diet, 172-173
- Obstetric complications of smoking, 193
- Ogna variant of epidermolysis bullosa, 1272
- Oil drop sign, 1177
- Onycholysis, 995
- Onychomycosis, 1016, 1017, 1172-1173
 - in children, 1387
 - differential diagnosis of, 1172, 1175
 - management, 1176, 1407-1408
 - from molds, 1176
 - subtypes and physical examination, 1173-1174
- Oral contraceptives. *See* *Contraceptives, oral.*
- Oral epithelium, examination of, 993
- Oral hairy leukoplakia, in HIV-infected patients, 1039-1040
- Organan, in heparin-induced thrombocytopenia, 643
- Orlistat (Xenical), for obesity treatment, 175
- Orthopedic surgery, thromboembolism prophylaxis in, 618-619
- Orthopedic trauma, thromboembolism prophylaxis in, 617-619
- Orthostatic hypotension, in older women, 132
- Osteoarthritis, of knee, management guidelines for, 94
- secondary, causes of, 92
- in women, 91-93
- Osteomyelitis, in diabetic foot, 958
- Osteoporosis, heparin-associated, 589, 645-653
 - incidence of, 649-653
 - mechanisms of action, 646-649
 - in women, 95-98
 - causes of, 96-97
 - genetic and lifestyle factors in, 96
 - older women, 132-133
 - pregnancy-associated, 651
 - prevention of, 96-97, 239-240
 - with hormone therapy, 309-310
 - treatment for, 97-98
- Ovarian cancer, prevention and detection of, 240-242
- Ovarian failure, premature, 298
- Overweight. *See also Obesity.*
 - definition of, 162
- Ovulatory dysfunction, and infertility in women, 279-280
 - androgen excess, 281-282
 - endocrine disorders, 282-284
 - hyperprolactinemia, 280-281
 - luteal phase defect, 280
- Paget's disease, 1315-1317, 1377
- Palpitations, during pregnancy, 251
- Pancreas transplantation, diabetic retinopathy and, 872
 - type 1 diabetes recurrence after, 740
- Papillomavirus infection, in children, 1384
 - in HIV-infected patients, 1036-1038
 - women, 339-341
 - warts from, 1025-1026
- Pap test, abnormal, management of, 225, 234-236
 - recommended frequency of, 235
- Papular urticaria, in HIV-infected patients, 1062
- Papules, 986, 990
- Papulosquamous and eczematous disorders, in children, 1389-1392
- Paralysis, with spinal cord injury, thromboprophylaxis for, 488
- Parasitic infections, in HIV-infected patients, 1049-1052
- Parenchymal hematoma, with intra-arterial plasminogen activator, 555
- Parkinson's disease, effect of smoking on, in women, 191-192
- Paronychia, 1176-1177
 - candidal, 1017-1019
 - differential diagnosis of, 1172
- Patches, 985
- Patch testing, 1117
- Pediatric dermatology, 1381-1403
 - benign skin neoplasms, 1286, 1292, 1300-1302
 - biopsy and medications, 1381-1382
 - congenital nevi, 1291-1292, 1327-1330
 - dermatologic manifestations of less common entities, 1401-1402
 - diagnostic techniques, 1383-1384
 - infectious disease, 1384-1388

- Pediatric dermatology (*Continued*)
 inflammatory skin conditions, 1392-1397
 neoplastic diseases, 1397-1400
 papulosquamous and eczematous disorders, 1389-1392
- Pediculosis, 1012-1015, 1100-1101
 in children, 1388
- Pelvic adhesions, and infertility in women, 286
- Pelvic inflammatory disease, in HIV infection, 344
 infertility and, 276-277
- Pemphigoid, bullous, 1252-1256
 cicatricial, 1256-1258
- Pemphigus, 1240
 differential diagnosis, 1249
 drug-induced, clinical manifestations, 1244, 1246
 diagnosis, 1249
 prognosis, 1251
 therapy, 1251
 paraneoplastic, clinical manifestations, 1246
 diagnosis, 1249
 prognosis, 1252
 therapy, 1251
- Pemphigus erythematosis, 1243
 prognosis, 1251
 therapy, 1250-1251
- Pemphigus foliaceus, clinical manifestations, 1243
 diagnosis, 1248
 prognosis, 1251
 therapy, 1250-1251
- Pemphigus vegetans, clinical manifestations, 1241, 1243
 diagnosis, 1247
 prognosis, 1251
 therapy, 1250
- Pemphigus vulgaris, clinical manifestations, 1240-1241
 diagnosis, 1247
 prognosis, 1251
 therapy, 1250
- Penicillamine, pemphigus from, 1244
- Penicillin, in syphilis, 1088
- Penicillium marneffei* infection, in HIV-infected patients, 1055
- Pentoxifylline, for diabetic retinopathy, 865-866
- Peptic ulcer disease in women, 28-35
 clinical manifestations, 31
 complications, 31-32
 diagnosis, 32
 management/medications for, 32-34
 pathophysiology, 28-29
 potentially related factors, 29-31
- Peptides, as thrombin inhibitors, 570-571
- Peptidomimetics, as thrombin inhibitors, 570
- Perforation, in gastroesophageal reflux disease, 24
 in peptic ulcer disease in women, 31-32
- Peripheral arteries, occlusion of, 517
- Peritoneal factors, and infertility in women, 285-286
- Permethrin 5% cream, 1012, 1051, 1099
- Petechiae, 987
- Phentermine, in obesity treatment, 175
- Phenylketonuria, 273, 1119
- Photochemotherapy, in psoriasis, 1140, 1410
 in vitiligo, 1202
- Photography, in melanoma diagnosis, 1339
- Photosensitivity, in cutaneous lupus erythematosus, 1223-1224
- Phototherapy, for depression in women, 363
- Phthirus pubis*, 1388
- Pigmentary diseases, **1185-1207**
 hyperpigmentation, 1185-1200
 hypopigmentation, 1200-1204
 melanin and, 1185-1187
- Pilar cysts, 1305
- Pityriasis alba, 1202-1203
 in children, 1389-1390
- Pityriasis lichenoides, dermatologic manifestations of, 1401
- Pityriasis rosea, 1118
 in children, 1391
 psoriasis versus, 1137
- Pityriasis versicolor, 1019-1020, 1186-1188
- Placenta, role of, in thyroid disease in pregnancy, 114-115
- Plaque, cerebral embolism and, 531-532
 skin, 987, 990
- Plasminogen activators, **545-568**
 direct intra-arterial delivery of, 552-559
 feasibility and safety considerations of, 559
 to vertebrobasilar artery territory, 557
 tissue-type, 550
 urokinase, 550-551
- Plasminogen deficiency, congenital, features of, 431
 thrombosis and, 430
- Platelet defects, prevalence of, 444-445
 thrombosis and, 442-444
- Plethysmography, in deep venous thrombosis diagnosis, 463
- Plummer's nails, 1182
- Pneumococcal vaccine, in women, high-risk factors for, 234
- Pneumocystis carinii* infection, cutaneous, in HIV-infected patients, 1051-1052
- Podophyllin, for genital warts, 1042, 1097-1098
- Podophyllotoxin, for genital warts, 1042, 1097

- Poikiloderma, in dermatomyositis, 1226
- Polymorphous light eruption (PMLE), 1119
- Polymyalgia rheumatica, in women, 93-95
- Polymyositis, 1224-1225
 - classification, 1225
 - clinical manifestations, 1228
 - evaluation, 1229, 1230
 - malignancy and, 1229
- Polytrichia, 1167
- Porphyria cutanea tarda, 1374-1375
 - in HIV-infected patients, 1062-1064
- Porphyrias, 1374-1375
- Port wine stains, 1301-1302
- Postherpetic neuralgia, 1023
- Postinflammatory hyperpigmentation, 1197-1200
- Potassium hydroxide (KOH) examination, 997, 1383
- Preconceptional counseling, infertility in women and, 272-275
- Prednisone, in myositis, 1229
- Preeclampsia, liver disease related to, 67-69
- Pregnancy, chronic medical problems affecting, 273
 - diabetes in, 823-845
 - carbohydrate metabolism changes and, 823-824
 - gestational diabetes, 831-838
 - diagnosis of, 834
 - fetal complications, 832-833
 - labor management in, 836
 - management of, 835-836
 - pathogenesis of, 831
 - postpartum, 837-838
 - screening for, 833-834
 - preconception diabetes, 824-831
 - fetal/neonatal considerations, 826-828
 - hemoglobin A_{1c} and malformation rate, 827
 - insulin regimen for, 830
 - management of, 828-831
 - delivery, 829-830
 - first trimester, 828
 - postpartum, 830-831
 - preconception, 828
 - second trimester, 828-829
 - third trimester, 829
 - maternal considerations, 824-826
 - hypoglycemic unawareness, 826
 - nephropathy, 825
 - neuropathy, 825
 - retinopathy, 824-825
 - vascular disease, 825-826
 - diabetic retinopathy in, 864
 - gallstones and, 53-54
 - gastroesophageal reflux and, 26-27
 - heparin treatment during, and osteoporosis, 652
 - inflammatory bowel disease and, 42-43
 - liver disease and, 63-69
 - acute fatty liver, 66-67
 - hyperemesis gravidarum, 64
 - intrahepatic cholestasis, 64-66
 - preeclampsia and eclampsia-related, 67-69
 - medical problems during, 249-269
 - antiphospholipid antibody syndrome, 260-261
 - cardiopulmonary disease, 251-256
 - diabetes mellitus, 258-260
 - infections, 261-265
 - human immunodeficiency virus, 261-263
 - tuberculosis, 263-265
 - systemic lupus erythematosus, 260-261
 - thromboembolic disease, 256-258
 - melanoma and, 1351-1352
 - normal, physiologic adaptations of, 250-251
 - rheumatoid arthritis and, 79-81
 - with substance abuse, 379
 - systemic lupus erythematosus and, 87-88
 - thromboprophylaxis in, 488, 620-621
 - thyroid disease in, 113-121
 - fetal thyroid, 115
 - Graves' disease, 117-118
 - human chorionic gonadotropin-induced hyperthyroidism, 118-119
 - maternal hyperthyroidism, 116-117
 - maternal hypothyroidism, 115-116
 - maternal thyroid physiology, 113-114
 - postpartum thyroiditis, 119-120
 - role of placenta, 114-115
 - thyroid nodules, 120-121
- Preretinal (subhyaloid) hemorrhage, in diabetic retinopathy, 856-857
- Procoagulant complexes, 603
- Progestin, in hormone replacement therapy, 302-304
- Progressive systemic sclerosis, 1235, 1363-1364
- Propionibacterium acnes*. See *Acne*.
- Protease inhibitors, in HIV-infected patients, 1035
- Protein C, activity of, 421
 - defects of, and thrombosis, 420-426
 - deficiency of, acquired, 422-423
 - congenital, 421-422
 - features of, 423
 - treatment of, 423
- Protein C cofactor, activated, defect of, 423-426
 - laboratory diagnosis of, 424-425
- Protein defects, blood, prevalence of, 444-445

- Protein restriction, in diabetic nephropathy, 893-895
- Protein S, defects of, and thrombosis, 426-429
deficiency of, acquired, 427-429
congenital, 426-427
characteristics of, 428
- Protein-sparing modified fast, for obesity treatment, 172-173
- Proteinuria, and antithrombin deficiency, 417
- Proximal motor neuropathy (amyotrophy), diabetic, 912
- Proximal subungual onychomycosis, 1173
- Proximal vein thrombosis, risk factors for, 479
in surgical patients, risk categories of, 615
- Prurigo nodularis, in HIV-infected patients, 1058
- Pruritic dermatoses, in HIV-infected patients, 1057-1062
- Pruritogenic mediators, 1108
- Pruritus, 1370
in atopic dermatitis, 1124-1125
- Pseudobubo, 1093
- Pseudomonas* infections, in HIV-infected patients, 1046
- Psoralen plus ultraviolet A light, in psoriasis, 1140
in vitiligo, 1202
- Psoriasis, **1135-1144**
in children, 1389
differential diagnosis of, 1136-1137
in HIV-infected patients, 1056
nails in, 1172, 1177-1178
quality of life and, 1136
treatment, 1137, 1409-1410
for generalized psoriasis, 1140-1141
for localized psoriasis, 1137-1140
in special areas, 1141-1142
- Pulmonary angiography, for pulmonary embolism diagnosis, 468-469
- Pulmonary disease, in women, **189-202**
- Pulmonary edema, during pregnancy, 253-255
- Pulmonary embolism, diagnosis, **459-576**
arterial blood gases, 467-468
ascending contrast venography, 466
chest radiography, 467
electrocardiogram, 467
evaluation for, 472
history, 460-461
laboratory evaluation, 470-471
modalities, 462-470
physical examination, 462
pulmonary angiography, 468-469
recommended strategies, 471-473
spiral computed tomographic angiography, 470
ventilation-perfusion lung scan, 468-469
emergency embolectomy for, 519
fatal, risk factors for, 479
in surgical patients, risk categories of, 615
incidence of, 410
in lupus anticoagulant-thrombosis syndrome, 438
prophylaxis, **477-493**
treatment, **495-510**
future perspectives on, 505-507
low-molecular-weight heparin, 501-502
- Pulmonary embolus, risk of, with estrogen-progestin hormone replacement therapy, 306
- Pulmonary hypertension, primary, preconception recommendations in, 273
- Purpura, 990
- PUVA therapy, in psoriasis, 1140, 1410
in vitiligo, 1202
- Pyoderma gangrenosum, 1222, 1369-1370
- Radiation therapy, in melanoma, 1352
- Radioactive iodine, for hyperthyroidism, 108
- Ramsay-Hunt syndrome, 1022
- Raynaud's disease, 1234
- Raynaud's phenomenon, 1233-1235, 1364
- Reinforcement, in behavioral therapy, for obesity, 170
- Reiter's syndrome, in HIV-infected patients, 1057
- Relationships, and depression in women, 364-368
- Renal function, in diabetic retinopathy, 862
- Renal insufficiency, cutaneous manifestations of, 1374
- Reproductive history, in infertility in women, 272
- Retinal detachment, traction, in diabetic retinopathy, 857-858
- Retinal vascular ischemia, direct infusion thrombolysis for, 559-560
- Retinal vascular thrombosis, incidence of, 410
- Retinoids, in acne, 1148-1149
- Retinopathy, diabetic. *See Diabetic retinopathy.*
- Revascularization, for coronary artery disease in women, 5
- Rheumatoid arthritis, cutaneous manifestations of, 1374
in women, 77-79
- Rheumatologic disorders in women, **77-101**

- antiphospholipid antibody syndrome, 89-90
 fibromyalgia, 90-91
 osteoarthritis, 91-93
 osteoporosis, 95-98
 polymyalgia rheumatica, 93-95
 rheumatoid arthritis, 77-79
 Sjögren's syndrome, 81-83
 systemic lupus erythematosus, 83-87
 drug-induced, 88-89
 hormonal factors and, 88
 and pregnancy, 87-88
 temporal arteritis, 93-95
 Ringworm of scalp, 1166-1167
 Rosacea, 1152-1153
 Roseola infantum, 1024
 Rubeosis iridis, in diabetic retinopathy, 859
- Sarcoidosis, 1375-1376
 in women, 198-199
Sarcoptes scabiei. See *Scabies*.
 Satiety, hunger and, in eating disorders, 149-150
 Scabies, 1011-1012, 1098-1100
 in children, 1387-1388
 differential diagnosis of, 1083
 in HIV-infected patients, 1049-1051, 1100
 therapy, 1408
 Scabies preparation, 997, 1384
 Scalp biopsy, 1157
 Scleredema, 1371-1372
 Scleroderma, 1231-1232
 eosinophilic fasciitis and eosinophilia myalgia syndrome, 1235-1236
 gastroesophageal reflux in women and, 28
 localized, 1232
 morphea versus, 1363-1364
 Raynaud's phenomenon and Raynaud's disease, 1233-1235
 systemic sclerosis, 1235
 Sclerosing hemangioma, 1296
 Sclerosis, systemic, 1235
 Sebaceous carcinoma, 1320-1321
 Sebaceous gland hyperplasia, 1305-1306
 Seborrheic dermatitis, 1118
 in children, 1390
 dermatomyositis versus, 1361-1362
 in HIV-infected patients, 1055
 Seborrheic keratoses, 1293-1295, 1332-1333
 Seizure disorders, preconception recommendations in, 273
 Self-in-relation theory of depression in women, 364-368
 Senescent alopecia, 1158-1159
 Sensory testing, quantitative, in diabetic neuropathy, 914-915
- Sentinel node biopsy, in melanoma, 1349-1350
 Sepsis, Sweet's syndrome versus, 1362-1363
 Serotonin, in eating disorders, 151-152
 Sexual abuse, and eating disorders in women, 374
 Sexuality, in older women, 137-138
 Sexually transmitted diseases, 1081-1104
 chancroid, 1089-1091
 differential diagnosis of genital ulcers, 1083
 epidemiology, 1081-1082, 1084
 genital herpes, 1094-1096
 genital warts, 1096-1098
 granuloma inguinale, 1092-1094
 lymphogranuloma venereum, 1091-1092
 pathogens in, 1082
 pediculosis pubis, 1100-1101
 prevention, 1101-1102
 scabies, 1098-1100
 syphilis, 1084-1089
 in women, HIV and, 337
 testing for, high-risk factors for, 234
 Sexual victimization, and depression in women, 366
 Shagreen's patch, 1204
 Shave biopsy, 999
 Shawl sign, 992
 Shingles, in HIV-infected patients, 1036-1037
 Sibutramine (Meridia), in obesity treatment, 175-176
 Single-chain urokinase plasminogen activator, for central nervous system diseases, 551
 Sister Mary Joseph nodule, 1377
 Sjögren's syndrome, in women, 81-83
 Skin, biopsy, 998-999
 in children, 1381-1382, 1384
 infections. See *Bacterial infections of skin*; *Fungal and yeast infections of skin*; *Viral infections of skin*.
 neoplasms. See also *Skin cancer*.
 benign, 1285-1307
 acrochordons, 1302-1303
 cherry (adult acquired) hemangiomas, 1298-1300
 childhood hemangiomas, 1300-1302
 cysts, 1303-1305
 dermatofibromas, 1295-1296
 keloids, 1297-1298
 melanocytic nevi, 1285-1293
 melanoma versus, 1288-1290, 1330-1334
 sebaceous gland hyperplasia, 1305-1306
 seborrheic keratoses, 1293-1295
 in children, 1397-1400

Skin (*Continued*)

- in HIV-infected patients, 1067
- Kaposi's sarcoma, 1070-1073
- lymphoreticular malignancies, 1069-1070
- primary cutaneous neoplasms, 1067-1069
- nail conditions, 1179-1181
- reactions to heparin, 653-654
- Skin cancer, melanoma, 1325-1358
- nonmelanoma, 1309-1323
 - basal cell carcinoma, 1310-1312
 - dermatofibrosarcoma protuberans, 1318-1320
 - epidemiology, 1309
 - histochemical stains in, 1312
 - keratoacanthoma, 1313-1315
 - Merkel cell carcinoma, 1317-1318
 - Paget's disease, 1315-1317
 - sebaceous carcinoma, 1320-1321
 - squamous cell carcinoma, 1312-1313
 - ultraviolet radiation exposure and, 1309-1310
- Skin examination, 981-999
 - adjuncts to, 996-999
 - description of lesions, 985-992
 - essentials of, 982-985
 - hair, 993-995
 - for melanoma, 1335-1336
 - mucous membranes, 992-993
 - nails, 995-996
 - in women, high-risk factors for, 234
 - Skin tags, 1302-1303
- Smoking in women, adverse effects of, 192-193
 - cessation of, 194-197
 - alternative agents, 197
 - nicotine replacement, 196-197
 - physician input, 195
 - programs for, 196
 - colon carcinoma and, 326
 - infertility and, 277
 - potential benefits of, 190-192
 - pulmonary disease and, 189-197
- Solar lentigo, 1332
- Somatization, anxiety and, in women, 368-371
- Spinal cord injury, with paralysis, thromboprophylaxis for, 488
- Spiral computed tomographic angiography, in pulmonary embolism diagnosis, 470
- Splinter hemorrhages, 1182
- Spongiosis, 1116
- Sporotrichosis, in HIV-infected patients, 1053-1054
- Squamous cell carcinoma, 1312-1313
 - in HIV-infected patients, 1068
 - of nails, 1172, 1181
- Staphylococcus aureus*, skin infection with, 1001, 1002, 1003, 1005, 1007, 1045, 1408
- Stasis dermatitis, cellulitis versus, 1364
- Stereotactic core biopsy, for breast disease in women, 211
- Steroids. *See* Corticosteroids.
- Stevens-Johnson syndrome, 1365
 - drug-induced, 1064, 1065
- Sticky platelet syndrome, diagnostic criteria for, 443
 - prevalence of, 444
 - thrombosis and, 442
- Stimulus control, in behavioral therapy, for obesity, 170
- Strawberry hemangiomas, 1300-1301, 1302
- Streptococcal gangrene, 1007
- Streptococcus pyogenes*, skin infection with, 1001, 1003, 1005, 1006, 1007
- Streptokinase, for central nervous system diseases, 551
- Stress, management, in behavioral therapy for obesity, 170
 - peptic ulcer disease and, in women, 31
- Stressful experience, definition of, 370
- Stress responses, definition of, 370
 - factors that modify, 371-373
- Strictures, in gastroesophageal reflux disease, 24
- Stroke, acute, thrombotic and thromboembolic, 549
 - common categories of, pathophysiology of, 528-535
 - early infarct signs in, 548
 - ischemic, definition of, 525
 - lacunar, 535-538
 - neurologic status and its measurement in, 547-549
 - in women, 10-12
- Strongyloidiasis, cutaneous, in HIV-infected patients, 1052
- Stucco keratoses, 1293-1294
- Subacute cutaneous lupus erythematosus, 1219-1221, 1360
- Substance abuse, in women, 378-381
 - older women, 138-139
- Sulfonylurea insulin secretagogues, for type 2 diabetes treatment, 769-770
- Sulfonylureas, for impaired glucose tolerance, 813-815
 - for older diabetic, in long-term management, 798
 - for type 2 diabetes treatment, 764-769
 - adverse effects, 767-768
 - comparison, 764-769
 - dosing, 768-769
 - efficacy, 765-767
 - mechanism, 765
- Surgery, dermatologic, 1411-1412

- in gastroesophageal reflux disease, 25
- for peptic ulcer disease in women, 34
- thromboprophylaxis in, 486, 618-619
- Surgical patients, thromboembolism prophylaxis in, 616
- venous thromboembolism in, risk categories of, 615
- Sweating abnormalities, with diabetic neuropathy, 913
- Sweet's syndrome, cellulitis or sepsis versus, 1362-1363
- Syndrome X, in diabetes, 934
- Synechiae, in infertility in women, 286-287
- Syphilis, 1007-1008, 1084-1089
 - course/stages of, 1084-1087
 - diagnosis, 1008, 1010, 1087-1088
 - differential diagnosis of, 1083
 - epidemiology, 1081
 - in HIV-infected patients, 1035, 1049, 1088-1089
 - women, 342-343
 - management, 1008, 1010, 1088-1089
 - secondary, 1008, 1009, 1085-1087
 - tertiary, 1087
- Syphilitic alopecia, 1157, 1163-1164
- Systemic diseases, cutaneous manifestations of, 1359-1379
- Systemic lupus erythematosus. See *Lupus erythematosus, systemic*.
- Systemic sclerosis, 1235, 1363-1364
- T cells, in eczema, 1116
 - in HIV-related skin diseases, 1034
 - subsets, in immune response regulation, 741-743
- Tamoxifen, for breast cancer prophylaxis, 242-243
- Tazarotene, in psoriasis, 1139, 1409
- Telangiectases, nail fold, 1182
- Telogen effluvium, 1159-1161
- Temporal arteritis, in women, 93-95
- Teratogens, agents suspected, 274
- Terbinafine, in onychomycosis, 1176, 1407-1408
- Terry's nails, 996, 1182
- Tetracyclines, in acne, 1150-1151, 1411
 - preconception recommendations, 273
- Th1 cell/cytokine-mediated immune response, in type 1 diabetes, 747-748
- Thiazolidinediones, for older diabetic, in long-term management, 799
 - for type 2 diabetes treatment, 777-779
- Thionamides, for hyperthyroidism, 108
- Thoracic surgery, thromboprophylaxis for, 486
- Thrombectomy, for deep venous thrombosis, 496-497
- Thrombin inhibitors. See also *Antithrombin agents*.
 - for anticoagulation, in heparin-induced thrombocytopenia, 644-645
 - cost considerations, 579-581
 - for deep venous thrombosis, 505-506
 - future trends in, 581-583
 - monitoring of, 578-579
 - overview of, 570-574
 - site-directed, developmental status of, 570
 - trials of, 575
- Thrombocytopenia, antiphospholipid syndromes and, 439
 - heparin-induced, 500, 589, 635-645
 - anticoagulant alternatives in, 642-644
 - clinical management of, 639-640
 - clinical manifestations of, 635-637
 - continued coagulation with, 640-642
 - future anticoagulants for, 644-645
 - laboratory assays on, 638-639
 - mechanism of action in, 637-638
 - thrombin inhibitors for, 576-577
 - types of, 636
- Thromboembolic disease. See also *Venous thromboembolism*.
 - during pregnancy, 256-258
 - prophylaxis for, preconception recommendations in, 273
- Thrombolytic agents, for deep venous thrombosis, 496
 - direct infusion of, 559-561
 - novel, for central nervous system diseases, 551
- Thrombophilia, hereditary, 414-418
- Thromboplastins, commercially available, origin of, 604
- Thromboprophylaxis, approaches to, 480-481
 - graduated compression stockings, 485
 - intermittent leg compression, 484-485
 - low-dose heparin, 481
 - low-molecular-weight heparin, 482-484
 - oral anticoagulants, 484
 - recommendations for, 486-488
 - high-risk patients, 487-488
 - low-risk patients, 486
 - moderate-risk patients, 486-487
- Thrombosis, cardiovascular disease and, 511-522
 - causes of, 411
 - cerebrovascular disease and, 523-544
 - coronary artery, 511-512
 - definition of, 525
 - diagnosis, 412
 - incidence in United States, 411
 - originating in cardiac chambers, 516-517
 - pathogenesis, 511

Thrombosis (*Continued*)

- prosthetic heart valves and, 515-516
- syndromes, **409-458**
 - antiphospholipid-thrombosis syndrome, 433-442
 - antithrombin defects and, 412-418
 - fibrinolytic system defects and, 429-432
 - heparin cofactor II defects and, 418-420
 - platelet defects and, 442-444
 - protein C defects and, 420-426
 - protein S defects and, 426-429
- Thrush, 1018, 1019
 - in HIV-infected patients, 1052-1053
- Thyroid, normal physiology of, 104
- Thyroid disease in women, **103-125**
 - hyperthyroidism, 106-109
 - hypothyroidism, 104-106
 - in pregnancy, 113-121. *See also Pregnancy.*
 - thyroid nodules, 109-113
- Thyroid disorders, cutaneous manifestations of, 1372-1373
- Thyroid function, depression in women and, 362-363
 - tests, in hyperthyroidism, 107
- Thyroiditis, postpartum, 119-120
- Thyroid nodules in women, 109-113
 - approaches to, 112
 - fine-needle aspiration biopsy of, 110
 - in pregnancy, 120-121
 - radionuclide imaging of, 111-113
 - ultrasound and, 113
- Thyroid-stimulating hormone test, in women, high-risk factors for, 234
- Ticlopidine, for diabetic retinopathy, 867
- Tinea barbae, 1015-1016
- Tinea capitis, 998, 1015, 1017, 1166-1167, 1387
- Tinea corporis, 1015
- Tinea infections, psoriasis versus, 1136-1137
- Tinea pedis, 1016, 1387
- Tinea unguium. *See Onychomycosis.*
- Tinea versicolor, 1019-1020, 1186-1188
- vittiligo versus, 1360-1361
- Tissue-type plasminogen activator, for central nervous system diseases, **545-568**
 - deficiency of, 430-432
- Tobacco, and peptic ulcer disease in women, 30
- Toes, gangrene of, in diabetes, 952
- Tolazamide, for type 2 diabetes treatment, 766
- Tolbutamide, for type 2 diabetes treatment, 766
- Toxic epidermal necrolysis, 1365-1366
 - drug-induced, 1064, 1065
- Traction alopecia, 1165-1166
- Transient ischemic attacks, in women, 9-10
- Trauma, multiple, thromboprophylaxis for, 487-488
- Traumatic event, definition of, 369
- Treponemal tests, 1087-1088
- Tretinoin, in acne, 1148-1149, 1411
- Triamcinolone, in acne, 1151
- Trichloroacetic acid, for genital warts, 1098
- Trichomegaly of eyelashes, 1066
- Trichotillomania, 1164-1165
 - in children, 1394
- Tricyclic antidepressants, as antihistamines, 1113-1114
- Tricyclic drugs, for diabetic neuropathy, 922
- Triglycerides, elevated, in diabetes, 935-936
- Trimethoprim-sulfamethoxazole, cutaneous eruption from, in HIV-infected patients, 1064
- Tripeptide derivatives, as thrombin inhibitors, 573
- Triple response of Lewis, 1107
- Troglitazone, for impaired glucose tolerance, 816
- Tubal factors, and infertility in women, 285-286
- Tuberculosis in women, during pregnancy, 263-265
 - skin test for, high-risk factors for, 234
- Tuberous sclerosis, 1203, 1204, 1401
- Tumors of skin. *See Skin, neoplasms.*
- Tyndall effect, 1190
- Tzanck preparation, 997-998, 1384
- Ulcerative colitis, in women, 39-41
- Ulcers, genital, differential diagnosis of, 1083
 - of legs, 1368-1370
 - skin, 987, 1410-1411
- Ultrasonography, in deep venous thrombosis diagnosis, 464-466
- Ultraviolet B therapy, in eosinophilic pustular folliculitis, 1060
 - in psoriasis, 1140
- Ultraviolet radiation, skin cancer and, 1309-1310, 1325-1326
- Urinary albumin secretion, in type 1 diabetes, with intensive vs conventional treatment, 885
 - primary versus secondary prevention, 670
- Urinary incontinence, in older women, 134-135

- Urokinase, for central nervous system diseases, 550-551
- Urticaria, 1106-1111
in children, 1393
evaluation, 1111-1112
management, 1112-1114
papular, in HIV-infected patients, 1062
- Uterine factors, in infertility in women, 286-287
- Uterine fibroids (leiomyomas), effect of smoking on, 191
and infertility in women, 287
- Vaginal atrophy, in menopause, hormone replacement therapy for, 308-309
- Valacyclovir, 1406
for herpes simplex infections, 1022, 1038, 1096
for varicella-zoster infections, 1023-1024
- Varicella lesions, 991
- Varicella-zoster virus infection, 1022-1024
in HIV-infected patients, 1036-1038
- Vascular disease, collagen. *See Collagen vascular diseases.*
- diabetic, 931-948
foot problems with, 951-952
maternal, progression in pregnancy, 825-826
in women, 6-15
aortic disorders, 6-8
aneurysm, 7
congenital, 6-7
dissection, 7-8
cerebrovascular disorders, 8-12
asymptomatic carotid stenosis, 9
stroke, 10-12
transient ischemic attacks, 9-10
peripheral vascular disorders, 12-13
peripheral venous disease, 12-15
- Vasomotor symptoms, in menopause, hormone replacement therapy for, 307-308
- Venous beading, in diabetic retinopathy, 850-852
- Venous stasis ulcerations, 1368-1369
- Venous thromboembolism, individual risk assessment for, 628
international consensus recommendations, 613-633
oral anticoagulants for, 502
pathogenesis, 477-478
prevention, 479-480
recommendations, 622-625
secondary, recommendations, 626-627
problem and need for prevention, 614-615
in medical patients, 615
in surgical patients, 614-615
risk factors for, 478-479
treatment, 591-594
heparin, 594
long-term, 502
low-molecular-weight heparin, 594
out-of-hospital, 595
recommendations for, 594-595, 625-626
surgical, 518-519
- Venous thrombosis, deep. *See Deep venous thrombosis.*
in lupus anticoagulant-thrombosis syndrome, 438
- Ventilation-perfusion lung scan, for pulmonary embolism diagnosis, 468-469
- Verrucae. *See Warts.*
- Verrucous lupus erythematosus, 1219
- Vertebrobasilar artery territory, ischemia of, 549
intra-arterial plasminogen activators for, 556-559
- Very-low-calorie diet, for obesity treatment, 172-173
- Vesicles, 987
- Vesicobullous diseases. *See Blistering diseases.*
- Victimization, and depression in women, 366
- Violence prevention screening protocol, 394
- Viral infections of skin, in children, 1384-1386
erythema infectiosum, 1028-1029
hand-foot-and-mouth disease, 1024-1025
herpes simplex, 1020-1022
in HIV-infected patients, acute exanthem, 1036
cytomegalovirus, 1038-1039
herpesvirus, 1036-1038
human papillomavirus, 1040-1043
molluscum contagiosum, 1043-1045
oral hairy leukoplakia (Epstein-Barr virus), 1039-1040
measles, 1029-1030
molluscum contagiosum, 1027-1028
roseola infantum, 1024
therapy, 1405-1497
Tzanck preparation for, 997-998
varicella-zoster, 1022-1024
warts, 1025-1027
- Vitamin K, pharmacology of, 602-603
- Vitamin K epoxide cycle, 602
- Vitiligo, 1200-1202
ash leaf macules versus, 1204
in children, 1397
tinea versicolor versus, 1360-1361
- Vitrectomy surgery, for diabetic retinopathy, 870-871

- Vitreous hemorrhage, in diabetic retinopathy, 857-858
- Vocal cord dysfunction, in women, 197-198
- Vomiting, pregnancy-related, effect of smoking on, 191
- Vulvovaginal candidiasis, in HIV infection, 341-342
- Vulvovaginitis, 1018
- Waist-to-hip ratio, calculation of, 166
- Warfarin, dermatologic surgery and, 1412
- Warfarin therapy, complications, 609
- dosage adjustments in, protocol for, 607
- future of, 609-610
- historical perspective, 601-602
- initiation, 606
- laboratory monitoring of, 603-605
- management, for major surgery, 609
- for minor surgery, 608
- problems, 607-609
- outpatient, 606-607
- patient assessment for, 605-606
- pharmacology, 602-603
- recommendations, 601-611
- Warts, 1025-1027
- in children, 1384
- genital, 1096-1098, 1385
- in HIV-infected patients, 1040-1043
- seborrheic keratoses versus, 1294
- therapy, 1407
- Weber-Cockayne type of epidermolysis bullosa, 1272
- Weight, body, regulation of, 163
- gain, in women, with smoking cessation, 194
- loss, and infertility in women, 277-278
- 1995 guidelines for, 165
- Wein-Penzing defect, and thrombosis, 442
- Wheals, 987
- White superficial onychomycosis, 1173-1175
- Whitlow, herpetic, 1021
- Willis, circle of, atherosclerotic plaque in, and cerebral embolism, 534
- Wiskott-Aldrich syndrome, 1119
- Women, breast disease in, 203-222
- cancer and, 321-333
- cardiovascular diseases in, 1-19
- depression in, 361-364
- domestic violence in, 391-401
- eating disorders in, 145-159, 373-378
- gastrointestinal diseases in, 21-50
- hepatobiliary diseases in, 51-75
- human immunodeficiency virus (HIV) disease and, 335-357
- infertility in, 271-295
- lymphangioleiomyomatosis in, 199
- mental health of, in primary care, 359-389
- obesity in, 161-181
- older, health of, 127-144
- pulmonary disease in, 189-202
- rheumatologic disorders in, 77-101
- sarcoidosis in, 198-199
- substance abuse in, 378-381
- thyroid disease in, 103-125
- vocal cord dysfunction in, 197-198
- Wood's lamp/light examination, 998, 1199, 1336-1337
- Xanthomas, 1367-1368
- Xerotic dermatitis, in HIV-infected patients, 1061
- Yeast infections of skin, 1017-1020
- Zidovudine, cutaneous complications from, in HIV-infected patients, 1064-1065, 1066
- hyperpigmentation, 1196

